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Genomics Courses 
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Background: Until recently, human genetics has primarily been used for research or 
targeted clinical testing. With the decreased cost and ease of access to genetic testing, there has 
been an expansion of the application of genetics to health and chronic disease states. The scalability 
of genetic testing has ushered in the era of Precision Medicine with integration of predictive 
modeling and genomics into health care. Historically, clinical genetics was limited geneticists 
supported by genetic counselors. However, with the massive expansion in access to genomic 
service, this prior model will not be able to meet the growing demand as genetics will now play a 
role in all areas of medicine. To integrate genetic services across the health care system, critical 
educational gaps will need to be addressed. Participatory genomic educational courses have been 
gaining popularity within genetics education because they include the opportunity for participants 
to undergo genetic testing and integrated applied learning modules. Test2Learn is a participatory 
education platform designed to teach adult learners about pharmacogenomics which was shown to 
increase the engagement of the learners by integrating the participatory element. Test2Learn has 
now been expanded to teach pharmacists, nurses, and primary care residents about 
pharmacogenomics and key precision medicine concepts.  In the most recent iteration presented 
in this thesis, Test2Lean has been expanded to provide education of whole genome sequencing 
(WGS) to a broad array of clinicians and key opinion leaders. 
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Objective: Create an online, participatory WGS and Precision Medicine educational 
program delivered in the Test2Learn platform that is scalable for different populations. 
Design: Develop a participatory educational program integrating the use of WGS data for 
adult, educated learners utilizing lessons learned from previous participatory genomics courses 
offered on the Test2Learn platform. 
Assessment: Analyze pre- and post- program surveys to gather data to enhance the 
development of the Mellon Whole Genome Sequencing (MWGS) course.  
Conclusion: Preliminary data in pilot programs shows that participation in the Test2Learn 
course significantly increased participants genetic knowledge and comfort level discussing genetic 
related issues with patients. Analysis of these results and current literature enhanced the creation 
of a novel, participatory WGS education program. 
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1.0 Introduction  
Historically, genetic testing has mainly been used for research or targeted clinical testing 
for specific indications. With the expansion of precision medicine initiatives, increase in direct-to-
consumer genetic test (DTC-GT) utilization, and growth in understanding of the role of genetics 
in different diseases, genetics has become more of a routine clinical tool similar to blood work or 
imaging. Some instances in which genetic testing has become more commonplace include cancer 
risk and family health history assessment, prenatal risk assessment, the genetics of chronic disease, 
and pharmacogenomics. Public surveys have shown that physicians believe that due to the 
innovation of next-generation sequencing (NGS), genetic testing use in clinical care will one day 
be the norm, but the viability of widespread implementation is still being explored through 
precision medicine research projects [1-3]. Many barriers still exist to widespread implementation 
of genetic testing including the lack of clinician knowledge and comfort talking about genetics, 
insurance coverage of testing, electronic health record (EHR) integration of results, and others. 
This thesis aims to address barriers to clinician knowledge and comfort working with genetics and 
to increase awareness of the clinical applications of whole genome sequencing (WGS) for both 
clinicians and key opinion leaders who may be involved in insurance and health system decision 
making around genomics. 
As testing becomes more available, many patients are turning to primary care physicians 
to help them manage their genetic results. Clinical management of genetic conditions and 
explanations of results is beyond current standard medical practice of primary care physicians. It 
is important to increase clinician knowledge and comfort discussing genetics to allow for 
appropriate medical management of patients. Incorporation of genetic advances in general medical 
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education has been significantly lacking over time despite the rise in genetic testing availability 
and utilization, which has resulted in current physicians not graduating with the knowledge 
necessary to meet the rapid growth of genetic technology and its application to health care [4-7].   
It is well recognized that a major barrier to the implementation of genetic testing in clinical care is 
this lack of education for clinicians and the resulting lack of confidence in including this 
information in medical management [7-10]. To date, there are few genetic medical education 
programs centered around the use of clinical grade genetic testing, such as whole genome 
sequencing and its use in clinical practice [4]. Similarly, there are no genetic education programs 
for key opinion leaders such as stakeholders in the payer process, policy decision makers and 
health care leadership. These individuals can help enable better insurance coverage for genetic 
testing, which would encourage the use of testing in the appropriate individuals. For widespread 
WGS use to be successful, more novel education opportunities are needed for clinicians and key 
opinion leaders (KOLs).  
One of the methods of education that has been integrated in genetics training over the last 
decade is participatory education. Participatory education is where participants use their own data 
in the educational program. This method has been shown to be an effective method of education, 
however, it has not been implemented very frequently. A few leading-edge educators have 
attempted to enhance graduate medical genetic education using participatory education.  Some of 
these attempts have included utilization of student and resident personal genetic testing 
information for educational purposes. Studies have found that this method encouraged student 
motivation and engagement [11]. Two such participatory educational programs are analyzed as 
part of this thesis project the Family Medicine Resident (FMR) program, offered through the 
University of Pittsburgh Test2Learn platform to family medicine residents, and the ACCOUNT 
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program, offered to select providers and community members from federally qualified health 
centers in Pittsburgh and Chicago. 
The Test2Learn (T2L) platform was created at the University of Pittsburgh specifically to 
enhance genomics educational programs through the use of personal genomic testing (PGT) and 
real genetic data [12]. One of the goals for development of the T2L platform was to ensure privacy 
of results. This goal was carried out through secure relay of PGT results to participants without 
retention of the results through the T2L platform and prevention of course faculty from accessing 
information regarding participant personal data. Previous studies using the T2L platform have 
shown increase in participant comfort and knowledge of genetics [12]. While the T2L platform 
has only been used for PGT like 23andMe, it has been expanded to integrate WGS data by other 
members of the research team in parallel to the work completed for this thesis project. 
Given the prior success of T2L to deliver high fidelity genetics education, the T2L team at 
the University of Pittsburgh was tasked and funded by the RK Mellon Foundation to develop a 
participatory WGS educational program, referred to as the Mellon Whole Genome Sequencing 
(MWGS) program. Once created, this program hopes to help close the gap in clinician knowledge 
of genetics and WGS, increase clinician comfort discussing and working with genetics, and 
increase KOLs awareness of genetic testing to advance access to genetic testing. Specifically, this 
program will integrate WGS data collected from course participants who choose to undergo 
sequencing as part of their educational program. The participatory educational MWGS program 
will be offered on the T2L and Canvas educational platforms to integrate genetic information and 
the educational materials online for ease of access and future scalability of the course. The 
sequencing will be completed at the UPMC Genome Center, a CAP/CLIA certified lab.  Certain 
results of the sequencing will be chosen and made available to course participants through the T2L 
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platform for use in overall learning objectives for the program. The curriculum development team 
includes a clinical pharmacist, physician, bioethicists, genetic counselors, and two graduate 
students, to ensure a comprehensive program. With the implementation of the CAP/CLIA certified 
genome center, nationally recognized Test2Learn educational program platform, and rich 
environment of genetic leaders and educators, the University of Pittsburgh is ideally situated to 
develop and implement this educational program. 
This thesis project is completed in parallel to the overall MWGS program development. 
The goals of this thesis are 1) to evaluate current literature involving genomics, including precision 
medicine projects and currently available genetic educational programs, and previous participatory 
educational programs including the T2L platform and 2) to create an educational program 
curriculum focused on the use of whole genome sequencing (WGS) in clinical care for both 
clinicians and key opinion leaders (KOLs) while using lessons learned from the evaluation 
conducted in the first goal to inform curriculum creation. 
1.1 Specific Aims 
1.1.1  Specific Aim 1 
Analysis of Previous Courses 
The Test2Learn program has been pioneering genetic education programs over the past 
eight years, with the most recent iteration of this program focused on educating family medicine 
residents (FMR), healthcare providers, and community leaders as part of the FMR and ACCOUNT 
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programs. These programs have published pre- and post- course data to give insight into the 
different areas of success and areas for improvement for both the MWGS curriculum and course 
evaluation materials. Analysis of this previous data will allow for iteration in the development of 
the curriculum for the MWGS course and the accompanying surveys. 
1.1.2  Specific Aim 2 
Curriculum Development 
A participatory course educating clinicians and KOLs on the clinical uses of WGS data in 
clinical care will be developed through utilization of literature searches and previous program 
analysis. The course will include input from team members with varying backgrounds to ensure a 
well-rounded and comprehensive curriculum that prepares clinicians to engage with patients about 
their genetics and the implication for WGS in healthcare for KOLs. The course will be offered on 
the Test2Learn platform and include opportunities to practice utilizing WGS data in an educational 
setting. A core set of learning modules will be developed with unique modules for the clinicians 
and KOLs relevant to their science background and anticipated implementation needs.  
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2.0 Literature Review 
As part of this thesis project, the currently published literature related to precision medicine 
and genomic medicine is reviewed to highlight key findings regarding genomics in medicine. The 
main purpose of this literature review is to provide insight into the need for genomic education, 
gaps in current genomic education availability, and identify topics to include/emphasize in the 
MWGS program curriculum. 
2.1 Precision Medicine Research Initiatives 
Many precision medicine projects are researching the benefits and limitations of using 
WGS in clinical spaces with the guidance of genetics professionals. Some programs also include 
evaluation of clinicians’ perceptions of working with genomic data, which can provide information 
on how to present genomic education effectively. Prior project data has been used to analyze the 
clinical utility of WGS and applicability of sequencing data in medical management. 
Unfortunately, most projects do not provide education for primary providers on long-term use and 
implications of the data returned to their patients, a gap the MWGS program is hoping to fill. While 
many of these projects are new and may still be ongoing, preliminary results for several of them 
have been published. These preliminary results help to shape what is needed in a novel WGS 
educational program curriculum. 
The PeopleSeq Consortium was created to analyze healthy adults that had undergone 
genome sequencing due to a genetic predisposition. This Consortium surveyed participants that 
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had received predisposition sequencing through one of four projects: HealthSeq, Personal Genome 
Project, Understand Your Genome, and Young Presidents’ Organization and MD/PhD Genome 
Projects. The goal of this consortium project was to examine the medical, behavioral, and 
economic outcomes of returning genomic sequencing information to healthy adults [13]. Of the 
1359 individuals from the projects included in the consortium, 543 completed surveys after 
receiving their genomic results and were included in this analysis [13]. Survey analysis revealed 
that participants were not deterred from pursuing testing by privacy or insurance discrimination 
concerns, an outcome also evaluated by the FMR and ACCOUNT programs and analyzed in this 
document. 
About half of participants who completed the surveys reported discussing their results with 
a healthcare provider, with PCPs cited as the healthcare provider in 81.1% of cases. This result 
emphasizes the need to provide educational resources to these providers. Testing decision regret 
was evaluated, which showed that 60.3% of participants reported no decision regret at all, and less 
than 3% of participants reported regretting their decision to have genetic testing or experiencing 
harm due to their decision [13]. The PeopleSeq Consortium is continuing to add additional projects 
and enroll additional participants as more precision medicine projects report genetic testing results 
to healthy individuals [13]. As additional projects enroll participants, there will be more healthy 
individuals with WGS data that will turn to their clinicians for assistance in medical management 
based on their results. It is important to ensure these clinicians have the educational resources to 
help them utilize this genomic data in their practice, supporting the need for a course such as T2L 
MWGS. 
One project, the MedSeq Project, created their own medical genetics education component 
to prepare the providers with information about how to incorporate WGS and standardized family 
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history assessment into standard clinical care. [13, 14]. Nine PCPs were recruited who then 
identified and recruited 8 to 12 of their eligible patients [14]. The education program for physicians 
included in this project has not been standardized and made widely available. The education 
included is described as a brief educational course consisting of 4 hours of case based online 
modules and two 1 hour in person group classes administered before patients were enrolled in the 
project. This timetable is important to consider when creating the MWGS program since it was 
short enough that busy clinicians could complete it but could still learn important genomic 
knowledge. 
Educational material included an orientation to the genome report that would be produced, 
which is an important aspect to appropriate medical management [13]. The WGS reports contained 
findings that are related to diagnostic indication, monogenic disease risk (MDR), carriers for 
recessive disorders, PGx for five drugs, blood group antigens, and complex-trait analysis [15]. 
These findings are commonly included in many laboratory WGS reports and are covered in the 
MWGS program. This study found that about 1 in 5 generally healthy patients receiving WGS 
results had a molecular diagnosis but only 1 in 25 had a new clinical diagnosis [16]. This supports 
that clinically appropriate medical management can result from WGS use in healthy adults, 
especially in the setting of genomic education and explanation of how to work with a clinical report 
for clinicians working with genomic data [16].  
The Geisinger MyCode Community Health Initiative and the All of Us Research Program 
are both precision medicine projects that initially focused on collecting health questionnaires and 
biological samples, such as saliva and blood. These samples were then analyzed and paired with 
the questionnaire data to make a biobank with phenotypic data so that data for a wide population 
could be utilized for precision medicine research [17, 18]. Both of these projects have been 
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recruiting for many years now and were initially focused on collecting data, with no detailed plans 
to return genetic results to participants [17, 18]. Since their initiation, both programs have now 
pivoted and launched efforts to begin returning results to participants [18, 19]. As they do so, data 
about the process of returning genetic results in a healthy population can be gathered to analyze 
the use of genetic results in medical management over time [20]. So far, the Geisinger MyCode 
samples have been used to generate molecular data, including high-density genotype and exome 
sequence data with over 180,000 exomes sequenced [21]. This massive amount of data is helping 
to further researcher understanding of many realms of the clinical applications of genomics, 
including polygenic risk scores (PRS) and prevalence rates of mutations, important information to 
share with providers in the MWGS program. 
Since initiation of returning results to participants, the Geisinger MyCode project has 
returned over 2,000 clinical results reports and continues to analyze the impact of returning these 
results [21]. The results reports currently include pathogenic or likely pathogenic variants in all of 
the ACMG SF version 2 genes (59 genes) and specific homozygous findings in the HFE gene [21].  
A total of 3.3% participants screened positive in the 60 conditions tested for, which is consistent 
with detection findings in previous studies. Of those that screened positive, 2.6-2.8% did not have 
a previous genetic diagnosis [21]. As these results are returned, participants may turn to their non-
genetics clinicians for guidance in using them in their medical management. It is important to 
prepare these clinicians with appropriate resources, such as the MWGS program. 
Within the Geisinger MyCode Project, an observational study was conducted that involved 
returning pathogenic and likely pathogenic variants associated with CDC tier one genetic 
conditions: hereditary breast and ovarian cancer syndrome, Lynch syndrome, and familial 
hypercholesterolemia. The CDC defines tier one genomic applications as “those having significant 
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potential for positive impact on public health based on available evidence-based guidelines and 
recommendations” [22]. For this study, results were given to 351 participants and then their 
electronic health record (EHR) was evaluated after disclosure for a prior genetic diagnosis, 
relevant personal and family history, post disclosure clinical diagnosis, and post disclosure risk 
management [19]. This study found that 87% of patients with a tier one finding were not previously 
diagnosed and that of these patients 65% of them had EHR evidence of relevant personal and/or 
family history of disease. With proper training and education, clinicians can potentially notice 
these relevant indications and implement genetics into their patients care earlier. This study also 
found that 70% of those not previously diagnosed had a recommended risk management procedure 
after results disclosure and 13% of those patients received a relevant clinical diagnosis after results 
disclosure [19]. Clearly, these results are impacting patient medical management, but it is 
important to ensure their providers are prepared to implement appropriate care or referrals. 
Due to research projects like PeopleSeq, MedSeq, and other precision medicine initiatives, 
the applications of clinical genetic testing have greatly expanded into a variety of areas of 
healthcare, such as carrier and cancer screening, tumor analysis, and pharmacogenomics (PGx) 
[23]. As medical management implications concerning WGS expand, education concerning the 
use of the results is essential to train clinicians to prepare them to decipher and utilize this 
information effectively in their clinical practice. These projects showed how far-reaching genomic 
results can impact clinical care and further support the need for accessible genomic education. 
 11 
2.2 Integration of Whole Genome Sequencing into Clinical Care 
To help test the viability of widespread integration of WGS use in clinical care, evaluation 
of different facets of implementation has been and continues to be conducted through precision 
medicine projects. The evaluation conducted by these projects has brought to light both barriers 
and opportunities for widespread implementation of WGS that are important to address and explain 
in the MWGS program as clinicians start to use WGS data and KOLs consider the benefits and 
limitations of covering WGS.  
2.2.1  Barriers 
Participants who consent to precision medicine research projects have been shown to have 
a relatively optimistic view of WGS, but perception of the clinical utility of genetic testing results 
does not necessarily mean the information is actually being used in a clinical setting [24]. In other 
words, while surveyed populations show a positive perception of clinical utility of genetic testing 
in the general population and show interest in utilizing this testing, this perception may not be 
mirrored by evidence-based practice experiences noted by these projects. Absence of actual 
clinical utility of testing results despite patient perception of utility may result in patients feeling 
that resistance to integration of genetic testing in clinical care is too paternalistic of KOLs. This 
tension may present another barrier to widespread integration of WGS use but may be able to be 
ameliorated with appropriate counseling on genetic testing, which are important factors to 
highlight in the MWGS curriculum. 
Another barrier to widespread implementation of WGS is the complexity of genome 
sequencing. This could result in a substantial number of individuals being falsely identified as at 
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risk for disease, which could result in a fatalistic response on the individual level. This can also 
result in unnecessary surveillance or procedures, or overutilization of healthcare resources [13]. 
The MedSeq project saw no patients whose molecular diagnoses clearly improved short-term 
health outcomes and the clinical value of the diagnoses made in this project was unclear [16]. As 
a program that is meant to educate on WGS, it is important to include this potential outcome of 
WGS for both clinicians and KOLs. 
Lab geneticists are also a limited resource necessary to evaluate novel variants identified 
by testing. Each novel variant identified requires considerable manual curation to determine their 
clinical significance, and interpretation of variants might not be apparent in the patient at the time 
of testing [23]. The burden of variant assessment has been studied and findings emphasize that this 
burden is the greatest during the initial phases of implementing a population scale genomic 
screening program [21]. This initial burden with limited lab genetics resources is a large barrier to 
widespread utilization of WGS. This initial burden of manual curation would also imply that 
returning carrier status for everyone undergoing WGS would significantly increase the amount of 
work done by clinical laboratories which may in turn increase turnaround time and cost for 
reporting all genetic results [23]. Since WGS is casting such a wide net and returns so many results, 
it is important to discuss this burden and potential impact on turnaround time with clinicians and 
KOLs as part of the MWGS curriculum.  
A barrier to utilization of WGS in clinical care that has been repeatedly noted is the lack 
of clinician readiness to integrate medical genetics into clinical practice [6, 7, 25-28]. While all 
doctors can order genetic tests to aid in the care of their patients, there can be unintended negative 
consequences; due to ordering the wrong test, ordering a test without appropriate patient consent, 
and wrongly interpreting testing reports; when a provider orders genetic testing without adequate 
 13 
training. As of 2002, of 1,120 primary care providers randomly surveyed in the United States, 60% 
of respondents had ordered genetic testing in their clinical practice and 74% had referred a patient 
for genetic testing [29]. Clinicians are ordering genetic tests and referring patients, and this number 
has most likely grown since 2002. Despite this, clinicians are still reporting a need for more 
education to help them integrate genetics into their clinical practice, and without it there is a high 
potential for unintended negative outcomes for patients. 
 A study evaluating GCs’ negative experiences when non-genetics providers order genetic 
testing was conducted to exemplify different unintended negative consequences. These could also 
be used to show opportunities for improved outcomes with educational intervention, which is why 
this aspect is included in the MWGS curriculum [30]. Phone interviews were conducted with 15 
GCs in Minnesota about negative outcomes experienced from genetic testing ordered by non-
genetics providers. They identified six domains that these negative consequences could be 
considered under: psychosocial/emotional effects, inadequate genetic counseling, errors related to 
genetic tests and screening, medical mismanagement, negative attitude toward medical 
provider(s), and unnecessary use of health care resources [30]. Regarding errors related to genetic 
tests and screening, all 13 cases had inaccurate information about interpretation of results, four 
had inappropriate genetic testing performed, four had incorrect genetic testing performed, and 
three had incomplete genetic testing [30]. Appropriate medical management of patients is 
imperative and is included in the MWGS program to help educate clinicians and also KOLs on the 
needs of clinicians to increase positive patient experiences. 
Appropriateness of medical management by non-genetics providers was also evaluated by 
the MedSeq project and in instances of inappropriate management were judged so because of 
undervaluation of the variant’s disease risk or miscommunication about its significance [16]. 
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Based on these descriptions of the themes and specific examples, implementation of additional 
education for clinicians and utilization of genetics providers could have prevented these situations 
from occurring. While this is a major barrier to utilization of genetics in primary care, it is also an 
opportunity for improvement and reinforces the need for novel education for clinicians, such as 
the MWGS program, to address this barrier. 
2.2.2  Opportunities 
Precision medicine projects also identified opportunities that widespread use of WGS may 
provide, which should be emphasized in a WGS educational program to both clinicians 
implementing the genetic testing but also KOLs who can support the use of genetic testing. One 
study noted that in the absence of a significant family history, a genomic screening approach might 
be the only way to identify an individual’s risk as a preventative measure [23]. Looking so widely 
for harmful changes also gives the chance for WGS to detect changes that can be harmful but not 
in a way that helps decipher a patient’s current symptoms, commonly referred to as secondary 
findings. Due to the ability to detect these secondary findings (SF), the ACMG published 
recommendations for providers on how to handle the reporting of these findings [31]. Their 
recommendations, referred to as ACMG SF, state that pathogenic changes associated with more 
prevalent mendelian inherited disorders that are adult onset and have treatments available should 
be offered to patients who undergo WES/WGS with the option to have these variants reported 
[31]. For example, if a patient undergoing WGS were to opt in to receiving ACMG SF variants in 
their results, an underlying BRCA mutation could be reported because there is screening and 
treatment available to patients with these mutations [32]. These types of results are not reported 
with genetic tests such as panel testing and need to be explicitly reviewed under the MWGS 
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program for clinicians. The downstream effects of secondary finding results must also be discussed 
with KOLs who are more interested in the big picture effect of utilizing WGS.  
 Results of this study also suggest that WGS might also expand the detectable phenotypic 
spectrum of disorders that are targeted by current newborn screening (NBS), identifying risk for 
NBS targeted conditions, such as hearing loss, in newborns who passed NBS. WGS can also detect 
non-classical presentations of disorders included in NBS, such as congenital adrenal hyperplasia, 
identifying this individual’s risk early, which may be beneficial by facilitating early diagnosis and 
therapies if needed [23]. Due to the wider net being cast by WGS, variants can be found in genes 
that might not be included on panel testing, either at the time of testing or in the future when 
genome sequencing data is reanalyzed [15]. WGS use may also expand on the current prevalence 
estimates of diseases with precision medicine projects detecting a rate higher than the known 
prevalence of certain conditions in the general population [23]. These are all important points to 
include in the MWGS curriculum to show the clinical applications of WGS as well as the 
differences between WGS and other testing technologies commonly used. 
Parents also anticipated benefits to testing healthy children that clinicians did not, including 
the ability to prepare and the benefit of knowledge for its own sake [24]. WGS data can be used 
throughout an individual’s lifetime for analyses of adult-onset disease risk and PGx for drugs used 
in the adult population. As more data is gathered through the years, polygenic risk estimates for 
complex traits could also be able to be used clinically [23]. Parents of children identified as high 
risk with adult-onset disease who are tested as a trio can also be detected as high risk and receive 
interventions they may not have considered or been eligible for without this information [23]. 
WGS allows detection of carrier status for a wide range of disorders that are not currently available 
in expanded carrier screening panels, an important point to show in the MWGS curriculum. 
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Having WGS done at an early age allows genomic information to be analyzed and put into 
an individual’s medical record, that can be specifically interrogated for new indications and inform 
personalized medicine applications to be accessible throughout an individual’s lifetime, a benefit 
of WGS that KOLs should be educated on. While WGS data might not be the most appropriate 
test at the time it is conducted, indication based analysis that takes a look at the WGS data based 
on new symptomology can be done as a rapid first tier test as the information is already available 
[13]. New gene-disease associations, novel disease variants, and new evidence on existing variants 
continue to be identified and can be used to reanalyze the sequencing data, which was done in the 
MedSeq project and resulted in new findings or updated results for participants [15]. Full 
reanalysis and reinterpretation of WGS results on an annual basis is likely to continue to yield new 
findings for individuals with sequencing data [15]. Widespread use of WGS would also require a 
reduced number of tests that must be maintained and validated as well as the ability to rapidly test 
individuals as new genes are implicated in disease since their results would only require reanalysis 
[15]. While any identified variants would require manual curation, the number of newly observed 
variants that would require manual curation within a cohort has been shown to drastically 
decreases as the size of the cohort increases [33]. So as more and more patients receive WGS, the 
burden of manual curation will decrease, another downstream effect of implementing WGS earlier 
that is important to emphasize to KOLs. 
Table 1: Key findings from precision medicine programs to include/emphasize in the MWGS curriculum 
Project Publication Area for Inclusion/Emphasis in MWGS Curriculum 
BabySeq Ceyhan-Birsoy, O., et 
al. (2019) 
In the absence of a significant family history, a genomic 
screening approach might be the only way to identify an 
individual’s risk as a preventative measure. 
WGS can also detect non-classical presentations of 
disorders, identifying an individual’s risk early which 
may be beneficial by facilitating early diagnosis and 
therapies if needed. 
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WGS use may expand on the current prevalence 
estimates of diseases with precision medicine projects 
detecting a rate higher than the known prevalence of 
certain conditions in the general population 
As more data is gathered through the years, polygenic 
risk estimates for complex traits could be able to be used 
clinically. 
Parents of children identified as high risk with adult-
onset disease who are tested as a trio can also be 
detected as high risk and receive interventions they may 
not have considered or been eligible for without this 
information. 
Pereira, S., et al. 
(2019) 
Parents anticipated benefits to testing healthy children 
that clinicians did not, including the ability to prepare 
and the benefit of knowledge for its own sake.  
WGS data can be used throughout an individual’s 
lifetime for analyses of adult-onset disease risk and PGx 
for drugs used in the adult population. 
MedSeq Machini, K., et al. 
(2019) 
Due to the wider net being cast by WGS, variants can be 
found in genes that might not be included on panel 
testing, either at the time of testing or in the future when 
genome sequencing data is reanalyzed. 
New gene-disease associations, novel disease variants, 
and new evidence on existing variants continue to be 
identified and can be used to reanalyze the sequencing 
data, which was done in the MedSeq project and 
resulted in new findings or updated results for 
participants. 
Full reanalysis and reinterpretation of WGS results on 
an annual basis is likely to continue to yield new 
findings for individuals with sequencing data. 
Widespread use of WGS would also require a reduced 
number of tests that must be maintained and validated as 
well as the ability to rapidly test individuals as new 
genes are implicated in disease since their results would 
only require reanalysis. 
Vassy, J.L., et al. 
(2017) 
In instances of inappropriate medical management by 
non-genetics providers were judged so because of 
undervaluation of the variant’s disease risk or 
miscommunication about its significance. 
PeopleSeq Zoltick, E.S., et al. 
(2019) 
Indication based analysis that takes a look at the WGS 
data based on new symptomology can be done as a rapid 
first tier test if WGS has already been conducted prior as 
the information is already available. 
Geisinger 
MyCode 
Mirshahi, U.L., et al. 
(2019) 
While any identified variants would require manual 
curation, the number of newly observed variants that 
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would require manual curation within a cohort has been 
shown to drastically decreases as the size of the cohort 
increases. As more and more patients receive WGS, the 
burden of manual curation will decrease 
CSER Amendola, L.M., et al. 
(2016) 
The downstream effects of secondary finding results 
identified by WGS. 
 
2.3 Current Medical Education and Graduate Medical Education 
Current medical education and graduate medical education are reviewed as part of this 
literature review to assess what genetic education is currently available to medical students and 
medical residents to assess overall clinicians’ preparedness on genomics. This review highlights 
the gaps in current education and also lessons learned from current non-participatory educational 
programs to utilize for the MWGS program. 
An attempt to survey the extent of genetic material covered in current medical education, 
was conducted in 2004 by the Indiana University School of Medicine. In the United States and 
Canada, 149 medical genetics course directors or curricular deans were surveyed about the 
material covered, number of contact hours, year in which courses were offered, and what 
departments sponsored the courses [10]. This data provided valuable baseline data about genetics 
curricula with a 75.2% response rate.  A major conclusion of the survey analysis was that 
improving the genetics curriculum in medical education would help train physicians that are 
knowledgeable of genetics concepts and comfortable discussing these concepts with patients while 
answering any questions the patient may have [10]. Of those programs that responded, 77% taught 
medical genetics in the first year with 66% devoting 20 to 40 hours to this instruction, largely 
focusing on general genetics concepts rather than practical applications of genetics [4, 10]. The 
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general genetics concepts most commonly reported to be taught were cancer genetics, 
multifactorial inheritance, mendelian disorders, clinical cytogenetics, and patterns of inheritance 
[10]. While most medical education programs include genetic information, it is usually fairly 
simple and does not prepare them for practical applications in genetics or the extent of genetic 
information being used in current healthcare practice [4]. This review confirmed that medical 
students are not getting enough medical genetics education, especially in practical applications in 
genetics. Due to this, a large portion of the application of genetics in medical management is 
included in the MWGS program. 
Recommendations on how to address these knowledge gaps and improve current medical 
education were published by Guttmacher in 2007, suggesting the utilization of patient care in 
addition to lectures on broad concepts to help strengthen medical education of practical 
applications of genetics [34]. These recommendations go on to state that medical student training 
should enable students to be able to correctly identify patients who require referrals to genetic 
specialists, understand frontline genetic testing and the interpretation of their results, and be able 
to provide informed consent to genetic testing [34]. In addition to addressing the knowledge gap 
in medical education on medical genetics, this would increase exposure to role models in medical 
genetics, an important factor in engaging medical students in medical genetics [34-38]. By training 
clinicians on medical genetics with the MWGS program, they can potentially impart this 
knowledge on their residents and students as well and further engaging medical students in 
learning about the applications of genetics in medicine. 
In 2014, the National Human Genome Research Institute convened an Inter-Society 
Coordinating Committee for Physician Education in Genomics to develop competencies that apply 
to all areas of practice on basic genomic skills. The working group developed five entrustable 
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professional activities: eliciting, documenting, and acting on relevant family history pertinent to 
the patient’s clinical status; using genomic testing to guide patient management; using genomic 
information to make treatment decisions; using genomic information to guide the diagnosis and 
management of cancer and other disorders involving somatic genetic changes; and using genomic 
tests that identify microbial contributors to human health and disease, as well as genomic test that 
guide therapeutics in infectious diseases [39]. These activities are included in the MWGS 
curriculum to help clinicians meet these competencies. 
While medical genetics is working its way into the medical education curriculum in a more 
profound way, many are also attempting to integrate genetic and genomic education into graduate 
medical education. In 2015, the Core Cardiology Training Symposium proposed that cardiology 
fellows should know principles of genetics, genomics, proteomics, metabolomics, and 
pharmacogenomics by the end of their fellowship to satisfy training requirements [40]. In 2017, 
the Brigham Genomic Medicine program was founded and proposed being used as a laboratory 
for education in clinical genomics to satisfy these training requirements, asking general cardiology 
fellows to present a clinical case to the program as an opportunity for exposure to medical genetics, 
enhancing their cardiology fellowship [41]. In 2019, the American Academy of Family Physicians 
published their revised recommended curriculum guidelines for family medicine residents in 
medical genetics which listed competencies, attitudes and behaviors, knowledge, and skills for 
family medicine residents [42]. These recommendations included competencies focused on the 
management of a clinical case involving genetics, from being able to conduct and communicate a 
risk assessment for a patient based off of personal and family history to recognizing their 
limitations and seeking appropriate consultation with other medical genetics providers [42].  These 
recommendations showed progress in medical programs attempting to bridge the genetics 
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knowledge gap with additional medical education and follow the framework proposed by the 
Competencies Working Group of the Inter-Society Coordinating Committee for Physician 
Education in Genomics [39, 42]. These recommendations and competencies were used heavily in 
the creation of the FMR program and will also help to shape the MWGS curriculum, aiming to 
help clinicians achieve these competencies. 
2.3.1  Participatory Programs 
Current participatory medical education and graduate medical education are reviewed as 
part of this literature review to assess what genetic education is currently available to medical 
students and medical residents. This review highlights the gaps in current education and lessons 
learned from current participatory educational programs to utilize for the MWGS program. 
An elective participatory genetic education program, where students could opt to undergo 
personal DTC-GT for analysis during the course, was developed in 2010 by the Stanford 
University School of Medicine for medical and graduate students [43]. This program was similar 
to the FMR and the MWGS program, with quantitative evaluation that provides insight for the 
creation of the MWGS program. Evaluation of the student experience of this course was mostly 
focused on qualitative outcomes of undergoing DTC-GT as part of the course and comparing 
knowledge gains between students who did and did not undergo genetic testing [43, 44]. Interview 
comment consensus with students who underwent DTC-GT fell under common themes: the 
pedagogical value of genotyping, attitudes towards clinical utility and application of genotyping 
results, perspectives on consultative support received, and experiences of informed consent [44]. 
Students that underwent DTC-GT agreed that utilizing their own genetic information throughout 
the course was personally motivating, engaging them in the course material and self-reporting a 
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better understanding of genetics because of pursuing testing, while also giving them perspective 
on what it is like to undergo genetic testing like their patients may choose to, giving them a 
personal experience they may share with a patient [43, 44]. This was supported with pre- and post-
course knowledge assessments that showed significantly higher knowledge than students who did 
not undergo DTC-GT [43]. Despite the positive reports of undergoing testing, students still relayed 
skepticism over the clinical utility of results concerned with complex disease and behavior, 
something many genetics professionals and the FDA, also regard with high skepticism [44-47]. As 
part of this course students could seek independent genetic counseling services and even though 
only one participant had training in clinical genetics, none of the students felt that utilization of 
these services should be required by the course [44]. One student stated plainly that as a 
biosciences student they could interpret the data themselves, but that the general public should be 
required to go through their doctors to get similar information [44]. While many reported they 
found the most utility in attempting to analyze the raw data from testing, they were dismayed that 
due to the anonymity of the course they could not utilize instructors as a resource to help in this 
analysis, showing a uniform need for help in analysis of their results [44]. In addition, when asked 
about details from the consent process of submitting their information for DTC-GT, none of the 
students could recall details of the consent agreement or any details of the biobanking agreement, 
although no students expressed any regret over pursuing testing despite having no recollection of 
the legal terms of this decision [44]. This experience emphasizes the need of inter-disciplinary 
discussions of the ethical, legal, and social implications of having students undergo genetic testing 
as part of a course and also the need for deliberate course topic management to educate on the 
risks, benefits, and limitations of different types of genetic testing, especially in the clinical setting. 
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In efforts to enhance the personalized medicine and genetic medical school curriculum at 
Tufts University School of Medicine, a multidisciplinary faculty group deliberated on the most 
appropriate way to introduce genomic education. The faculty group initially proposed that a small 
subset of first year medical students in the year 2009 would undergo DTC-GT as part of their 
genetics course and complete surveys and interviews to help examine the impact that this could 
have on student education without exposing the whole class, in case negative side effects were 
seen [48]. After discussions both within the faculty group and with the IRB, it was decided that all 
students should have engagement with DTC-GT but that it would be with randomized data 
provided by 23andMe [48]. While this course didn’t directly involve a participatory aspect for 
students, the creation of the course did reveal many considerations programs should take before 
implementing personalized genetics into their medical school curriculum [48]. While they agreed 
that integration of genomic education into the curriculum is necessary to prepare students, a 
multidisciplinary team should be involved in the creation of the course and the IRB team should 
be involved very early in the process, a plan should be in place to protect privacy of students 
especially in the case of abnormal results that may require follow up, and discussion of the benefits, 
limitations, and potential harms of testing should be included in the curriculum [48]. Early 
interrogators of the integration of DTC-GT into the medical school curriculum such as Stanford 
and Tufts have provided important groundwork for the implementation of personal testing into 
medical education course work. 
In 2012, the Icahn School of Medicine at Mt. Sinai implemented a two-part laboratory style 
genomics course that allowed students to analyze their own whole genome. Initially with the 
introduction of the “Practical Analysis of Your Personal Genome” course (PAPG), many students 
expressed interest in undergoing sequencing, but many reported decisional conflict [49]. In 2013, 
 24 
to prepare students for the PAPG course and address the decisional conflict reported prior, students 
were required to complete the prerequisite “Introduction to Human Genome Sequencing” 
workshop (IHGS) [50]. Significant reduction in reported decisional regret was noted in 2013 after 
the addition of the IHGS workshop, but no analysis between students who did and did not undergo 
testing was available at this time because all 19 students decided to undergo personal genome 
sequencing [50]. This class also reported a significant increase in technical WGS knowledge, with 
interview analysis additionally suggesting that personal genome sequencing increased student 
motivation to learn and also understanding of the patient genetic testing experience [50].  
Additional analysis of this class was done, including data collected from students enrolled 
in the IHGS workshop and subsequent PAPG course in 2013, 2014, and 2015. Of the 59 students 
enrolled in the PAPG course, 56 chose to undergo genome sequencing with baseline decisional 
conflict decreasing through the years [11]. This longitudinal analysis reinforced the previous 
report, also reporting a significant increase in technical WGS knowledge, with interview analysis 
additionally suggesting that personal genome sequencing enhanced the genomics pedagogy, 
increasing student motivation to learn and also understanding of the patient genetic testing 
experience [11]. Additionally, the vast majority (90%) of students also reported spending time 
outside of mandated assignments analyzing their genome, similar to the students enrolled in the 
Stanford program [11, 43]. This course showed the merit in including personal genome sequencing 
in medical education, but further analysis will be necessary to quantitively show whether or not 
PGS is more effective than other educational approaches, such as having students use anonymous 
data or personal DTC-GT as part of a participatory medical educational program in genetics. 
Here at the University of Pittsburgh in 2016, a genetics educational platform, Test2Learn, 
was initially developed to teach pharmacogenomics to pharmacy students with the ability to 
 25 
integrate a participatory aspect with testing from 23andMe in the Test2Learn platform. For this 
program, 122 second-year Doctor of Pharmacy (PharmD) students in a required course were 
offered DTC-GT for personal genetic testing (PGT) as part of a larger program approach to teach 
pharmacogenomics [12]. Participating students could choose to either go through PGT and use 
these results during the course or utilize randomized, anonymous data provided by the research 
team, with 100 students (82%) choosing to undergo PGT [12]. Analysis showed significant 
improvements in  knowledge on multiple assessments, with genotyped students reporting a greater 
increase in confidence in understanding test results and self-perceived ability to empathize with 
patients compared to those not genotyped [12]. Additionally, most students (71%) reported that 
PGT was an important part of the course, with 60% reporting they had a better understanding of 
pharmacogenomics specifically because of the opportunity to undergo PGT [12]. While this 
program is not for medical students or residents, it piloted the Test2Learn program, which has 
since been used in additional participatory graduate medical education programs at the University 
of Pittsburgh. 
Family medicine residents at the University of Pittsburgh were offered the opportunity to 
participate in an innovative, CE-accredited program incorporating optional PGT using 23andMe 
and/or working with anonymous genetic data to achieve the genomics competencies established 
by the AAFP and Korf et al [39, 42]. Analysis of this program data is completed and discussed 
later in this document as part of the lessons learned aspect of this project.  
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2.4 Current Continuing Medical Education 
Current continuing medical education programs are reviewed as part of this literature 
review to assess what genetic education is currently available to clinicians. This review highlights 
the gaps in current education and resources from non-participatory educational programs to utilize 
for the MWGS program. 
The AMA has a page on their website dedicated to education and resources in genetics and 
personalized medicine for physicians that were reviewed for the MWGS curriculum. They include 
links to educational modules they have created, the Genetics in Primary Care Institute resource 
repository, and also the Genetics/Genomics Competency Center (G2C2) [51]. The G2C2 
educational material repository collects and catalogues educational resources according to the 
National Human Genome Research Institute Inter-Society Coordinating Committee for Physician 
Education in Genomics competencies that apply to all areas of practice on basic genomic skills for 
physicians [39, 52]. The educational material included in G2C2 comes in various formats, from 
webinars to fact sheets and self-study activities, many of which allow physicians to earn continuing 
medical education credits [52]. While G2C2 contains a large amount of educational material, as 
genetic technology continues to advance and our understanding of the clinical applications of 
genetic information increases, educational materials will continue to be developed to educate 
providers and added to this repository [52]. Many believe the next step in the evolution of these 
educational materials is participatory continuing medical education programs such as the MWGS 
course since the efficacy of participatory continuing and graduate medical education is shown [7, 
25, 53]. 
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2.4.1  Participatory Programs 
Current continuing medical education programs are reviewed as part of this literature 
review to assess what genetic education is currently available to clinicians. This review highlights 
the gaps in current education and lessons learned from participatory educational programs to utilize 
for the MWGS program. 
A participatory aspect was included in a recent study by Haga et. al. where primary care 
professionals obtained DTC-GT and, while it wasn’t paired with medical education, the experience 
of undergoing personal genetic testing reportedly increased providers’ comfort in discussing 
genetics with their patients [7]. In this study, 130 primary care physicians underwent DTC-GT and 
answered pre- and post-testing surveys, with 62% indicated they had not received any formal 
genetics training, with the majority of those indicating undergoing genetics education stating that 
it was received in medical school. Of note, respondents that indicated they had some formal 
medical genetic education in medical school had graduated more recently than those who had not 
had any genetic education exposure in medical school [7]. In surveying the impact of undergoing 
PGT on PCP’s, self-reported comfort discussing patient’s health status, genetics, and disease risk 
race/ethnicity increased significantly, with 53% of participants also indicating that they planned to 
participate in genomic medicine educational activities, such as a CME course or conference [7]. 
When asked about preferred mode of educational activity, the modality ranked first most 
consistently was online CME programs, with 42% of respondents ranking this modality as their 
preferred mode of education for genomic medicine. The indicated preference of online based CME 
program and significant reports of increased comfort in discussing genetics with patients highlights 
a unique opportunity to combine these two aspects into an educational program for providers on 
genomics.  
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As part of the FMR program, family medicine residents at the University of Pittsburgh 
were offered the opportunity to participate in an innovative, CE-accredited program incorporating 
optional PGT from 23andMe and/or working with anonymous genetic data to achieve the 
genomics competencies established by the AAFP and G2C2. As part of the ACCOUNT program, 
healthcare providers and community leaders in Pittsburgh and Chicago collaborated with the T2L 
team to assess the feasibility of a participatory educational PGx program designed to enhance 
participant knowledge. Participants were given the option to undergo PGT from 23andMe or work 
with anonymous genetic data during the program [54]. Analysis of the data from these programs 





Genetic literacy is low among non-genetics medical providers, a knowledge deficit that is 
widely reported by providers in primary care [25, 55, 56]. Despite this known knowledge deficit, 
patients report that they expect their primary care providers to be involved in integrating their 
genetic information into their clinical care, while providers report that they are open to discussing 
genetics but require better resources [1, 6, 25, 55]. With an increasing number of patients 
considering genetics to be instrumental to their healthcare, equipping providers and collecting data 
on the impact of genetics in clinical care is more necessary than ever [57]. In addition to genetic 
education in medical school, continuing education in genetics should be widely available for 
clinicians as well as key opinion leaders (KOLs), such as those in the insurance industry or hospital 
executive officers [34].  
In 2019, the Robert K Mellon Foundation funded the creation of a high-fidelity, web-based 
participatory educational program on whole genome sequencing (WGS) use in clinical care after 
identifying the critical need for engaging and accessible education. This program, known as the 
Mellon Whole Genome Sequencing (MWGS) program, aims to drive genomic knowledge, 
facilitate WGS result interpretation, and explore the utility of genetic testing. The educational 
resources of this program are web-based and available on Canvas and the Test2Learn (T2L) 
platform as scalable educational opportunities. Previous participatory educational programs using 
the T2L platform have shown marked improvements in many surveyed areas, including a 
significant increase in participant comfort discussing genetics with patients. Participants are 
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expected to be frontline practitioners, emerging professionals, and KOLs who are ideally 
positioned to rapidly advance WGS in clinical practice. The recruitment of program participants 
and release of the educational program, including collection of pre- and post-course evaluations, 
are scheduled to launch in September 2021 at the Precision Medicine World Conference (PMWC) 
being held at the University of Pittsburgh. 
To prepare for the development of the curriculum for the MWGS program, review of the 
current literature was conducted to examine current precision medicine implementation projects, 
current state of medical and post-medical education in genomics and participatory genomics 
education. This review yielded several key findings including: participants of programs receiving 
WGS results are turning to non-genetics clinicians for help interpreting their results into their 
clinical care; the current lack of education available to clinicians to help them understand the 
complexities of genetic results and the need to introduce clinicians to resources that can help them 
implement genetic results into patient care; the need for novel education for KOLs in insurance to 
educate them on the expanding uses of genetics and the need for increased insurance coverage and 
access; and the increase in access to genetic testing that widespread education of clinicians and 
increased coverage of genetic testing by insurance could bring to patients.  
Review of current educational programs available to medical students, residents, and 
clinicians was also done to highlight areas to include and emphasize in the MWGS program 
curriculum. These areas included the differences between different genetic testing technologies, 
the difference between genetic testing results, and the application of genetic testing results in 
clinical care. Review of programs confirmed that most medical students are not graduating with 
the knowledge needed to understand and interpret genetic results. Two of the programs reviewed 
were the Pitt implemented Test2Learn programs, ACCOUNT and FMR. 
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To prepare for the pre- and post-course survey development for the MWGS course, 
analysis was done on the data collected from two previous T2L iterations, including the 
ACCOUNT and FMR educational programs. As part of the ACCOUNT educational program, 43 
providers, 14 in Chicago and 29 in Pittsburgh, and 18 community members, 8 in Chicago and 10 
in Pittsburgh, were recruited to complete a participatory educational program using the T2L 
platform. This program aimed to educate participants on precision medicine with the option of 
undergoing personal genetic testing. Pre- and post-course survey data was collected from 
participants. The Family Medicine Resident (FMR) educational program is part of a study testing 
personal genetic testing as a method of teaching essential genomic competencies for family 
medicine residents. Specifically, this program aimed to create a genomics education program that 
is designed to achieve competencies outlined by the Genetics-Genomics Competency Center 
(G2C2) and the American Academy of Family Practice. As part of this study, 65 participants 
completed pre-course surveys and 18 participants completed post-course surveys. The literature 
review findings along with analysis of the ACCOUNT and FMR programs will give insight into 
the gaps in current educational programs, areas for emphasis in the MWGS curriculum, and 
effectiveness of previous medical genetic education programs. 
 
3.2 Methods 
The FMR and ACCOUNT studies were approved under Expedited Review, with a waiver 
of informed consent and HIPAA authorization, by the University of Pittsburgh Institutional 
Review Board (IRB) and University of Chicago Institutional Review Board (IRB), respectively 
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(PRO17040285, 2018-0449) (Appendix A). As the subsequent curriculum creation has not 
recruited participants or gathered data, no IRB approval was necessary. Once the course is created 
and ready to be launched, IRB approval will be pursued in compliance with University of 
Pittsburgh Institutional Review Board research requirements. 
3.2.1  Data Analysis of ACCOUNT and FMR Programs 
Pre- and post- course surveys were available on either paper or on Qualtrics and completed 
by educational program participants for both the ACCOUNT and FMR education programs. 
Surveys that were completed on paper were entered into Qualtrics for ease of research team access. 
Provider participants of the ACCOUNT program received a copy of the pre-course survey included 
in Appendix B.1.1 and post-course surveys included in Appendix B.1.3. Community participants 
of the ACCOUNT program received a copy of the pre-course survey included in Appendix B.1.2 
and post-course surveys included in Appendix B.1.4. Participants of the FMR program received 
a copy of the pre-course survey included in Appendix B.2.1 and post-course surveys included in 
Appendix B.2.2. The pre- and post-course surveys for each program and population were similar 
but not identical. Survey questions were divided into sections on demographics, knowledge of 
genetics and pharmacogenomics, and attitudes and perceptions regarding the use of 
pharmacogenomics and precision medicine in primary care. Analysis of survey questions included 
below is organized in the order that it appears in the surveys.  
FMR program and ACCOUNT Pittsburgh program data was accessed through Qualtrics 
2021 and downloaded to both Microsoft Excel and IBM SPSS for analysis. ACCOUNT Chicago 
program data was accessed through Microsoft Excel sent from the Chicago research team. This 
data was then manually entered into SPSS for statistical analysis. The coding for each SPSS 
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document was automatically created when the data was downloaded from Qualtrics and was not 
consistent between SPSS documents and required manual entry in certain cases. Additionally, 
some variable types were incorrectly imported and were manually changed to accurately reflect 
the variables recorded. Data sets were manually combined in SPSS for analysis and additional 
variables were entered that were not originally included in the surveys to delineate data sets for 
analysis. For example, a pre-/post- variable was added in all data sets.  
Attitudes and perception questions data from the FMR and ACCOUNT surveys was 
analyzed using Qualtrics 2021 and Microsoft Excel for descriptive statistical analysis. The survey 
data for the ACCOUNT and FMR programs was downloaded from Qualtrics to be cleaned 
(removal of excluded data) and analyzed using IBM SPSS Statistics 27 for quantitative statistical 
analysis. Data that was excluded were participant surveys that did not complete at least 50% of the 
knowledge questions in either the pre- or post- course survey as this was deemed the most 
important data point by the research team. The survey responses were not paired between pre- and 
post-course surveys due to issues with the linkage system. True/false knowledge question data was 
analyzed using Mann-Whitney U test or Welch’s t-test and self-assessment of genetics knowledge 
was analyzed using Mann-Whitney test as initial analysis showed unequal variances in the data. 
For the self-assessment of genetics knowledge questions, analysis was done on the topic areas of 
pharmacogenomics, genetics of complex diseases, basic genetic principles, and precision medicine 
for provider participants. For analysis of community member participants, analysis was done on 
the topic areas of understanding of the concept of pharmacogenomics and understanding of the 
concept of precision medicine. This analysis was selected due to the relevance to the MWGS 
educational program.  
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Available survey data that was used for analysis is outlined in the table below. All 
participants completed a pre-course survey, and all subsequent descriptive analysis utilizes these 
numbers for calculations.  
Table 2: Surveys available for analysis by program, population, and timepoint 




FMR Program Healthcare Provider 65 18 
ACCOUNT Program Healthcare Provider 43 30 
Community Member 19 16 
3.2.2  Curriculum Development 
A participatory medical genetic education program curriculum will be created for both 
clinicians and KOLs focusing on WGS data. The educational modules will be available to 
participants on the Canvas teaching platform, as web-based, scalable educational modules with 
access to WGS through the T2L platform.  
To create the curriculum, a landscape analysis of educational programs was completed. 
Search strategy queried 1) EMBASE and PubMed with keywords “whole genome sequencing”, 
“medical education”, “participatory education”, “health care personnel”, and “education program” 
from inception to 2020; 2) NHGRI’s Genetics-genomics competency center (G2C2) website using 
search terms “genetics” and “clinical genetics”; and 3) internet searches to identify programs that 
may be unpublished.  Titles and abstracts were evaluated, and full articles reviewed when deemed 
applicable (i.e., describing WGS educational programs). Similar records were then sought in 
EMBASE using keywords derived from highly relevant articles to extend the search. Abstracted 
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information focused on education methods including program goals, target audience, length of 
program and its structure, learning methods, topics, and learner outcome metrics analyzed. A 
multidisciplinary group with expertise spanning primary care, ethics, basic science, informatics, 
clinical implementation, public health, and pharmacogenomics completed a gap analysis and, in 
alignment with G2C2 competencies, developed topics targeting unmet needs for specific audiences 
of clinicians and KOLs. Consensus learning objectives were constructed through iterative 
development within each topic with the intent of being used in continuing education approved 
programs. 
3.3 Results 
3.3.1  Analysis of Previous Genomic Educational Programs 
The FMR program has been implemented at UPMC Altoona Family Medicine and UPMC 
Shadyside Family Medicine in Pennsylvania and the Family Medicine Rural Residency Programs 
of Caldwell and Nampa Idaho. There are 67 total participants from the FMR program included in 
this analysis. The ACCOUNT program has been implemented in Chicago and Pittsburgh, 
including providers and community members in both locations. There are 43 total healthcare 
provider participants and 18 community leader participants from the ACCOUNT program 
included in this analysis. Pre- and post-course surveys responses from each location were pooled 
before analysis. The survey sections that are included in this analysis are divided into three parts: 
demographics, knowledge of genetics and pharmacogenomics, and attitudes/perceptions regarding 
the use of pharmacogenomics and precision medicine. 
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3.3.1.1 Demographics 
Demographics for participants is summarized in Table 3 below, all demographic data was 
pulled from pre-course surveys as post-course surveys did not include demographic questions. Out 
of FMR respondents, the most commonly reported age group (71.6%, n=48) was reported to be 
between 25 and 34 years of age, believed to be due to the targeted resident population of this 
program. The fewest number of respondents (1.5%, n=1) were reported to be between 18 and 24 
years of age and over 64 years of age. Out of ACCOUNT respondents, the majority of participants 
indicated they were over 35 years of age, with the largest proportion of community member 
respondents indicating they were over 64 years of age. Out of all respondents, the majority identify 
as female (62.5%, n=80). Ethnicity was only surveyed in ACCOUNT community members so 
there is no analysis of this information. The majority of FMR respondents (68.7%, n=46) identified 
that they were physician residents. The majority of ACCOUNT provider respondents identified 
that they were either doctors (25.6%, n=11) or nurses/medical assistants (30.2%, n=13). All 
ACCOUNT community respondents identified that they were either community board members 
(44.4%, n=8) or “other” (55.6%, n=10). Providers were then surveyed on when they completed 
their advanced degree, including MD, DO, and PharmD as examples of advanced degrees. The 
majority of FMR respondents indicated after the year 2011 (74.6%, n=50) while the most 
commonly reported answer for ACCOUNT providers was “not applicable” (32.6%, n=14) by 
nurses, staff, and “other” that did not feel that their education qualified as an advanced degree. 
Additionally, providers were surveyed on their highest level of previous genetic education with 
10.2% (n=13) indicating no previous genetics education, 43.8% (n=56) indicating a biology course 
as their previous education, 28.1% (n=36) indicating they had taken a specific course on genetics, 
1.6% (n=2) indicating they had taken a specific course or training on pharmacogenomics. 
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Table 3: Demographics of previous program participants by program and participant group 













18 to 24 years 1.5% (n=1) 2.3% (n=1) 5.6% (n=1) 2.3% (n=3) 
25 to 34 years 71.6% (n=48) 11.6% (n=5) 0% (n=0) 41.4% (n=53) 
35 to 44 years 10.4% (n=7) 23.2% (n=10) 5.6% (n=1) 14.1% (n=18) 
45 to 54 years 9.0% (n=6) 34.9% (n=15) 38.9% (n=7) 21.9% (n=28) 
55 to 64 years 6.0% (n=4) 23.2% (n=10) 5.6% (n=1) 11.7% (n=15) 
65 or more years 1.5% (n=1) 4.7% (n=2) 44.4% (n=8) 8.6% (n=11) 
Gender Identity 
Male 40.3% (n=27) 23.2% (n=10) 44.4% (n=8) 35.2% (n=45) 
Female 55.2% (n=37) 76.7% (n=33) 55.6% (n=10) 62.5% (n=80) 
Not Listed 4.5% (n=3) 0% (n=0) 0% (n=0) 2.3% (n=3) 
Current Position 
Physician Resident 68.7% (n=46) 0% (n=0) 0% (n=0) 35.9% (n=46) 
MD/DO 19.4% (n=13) 25.6% (n=11) 0% (n=0) 18.8% (n=24) 
NP/PA 3.0% (n=2) 11.6% (n=5) 0% (n=0) 5.5% (n=7) 
RN/MA 0% (n=0) 30.2% (n=13) 0% (n=0) 10.2% (n=13) 
Staff 0% (n=0) 14.0% (n=6) 0% (n=0) 4.7% (n=6) 




0% (n=0) 0% (n=0) 44.4% (n=8) 6.3% (n=8) 
Year of advanced degree completion (MD, DO, PharmD) 
Before 1990 4.5% (n=3) 14.0% (n=6) n/a 7.0% (n=9) 
1991-1995 6.0% (n=4) 4.7% (n=2) n/a 4.7% (n=6) 
1996-2000 1.5% (n=1) 11.6% (n=5) n/a 4.7% (n=6) 
2001-2005 0% (n=0) 4.7% (n=2) n/a 1.6% (n=2) 
2006-2010 6.0% (n=4) 14.0% (n=6) n/a 7.8% (n=10) 
2011+ 74.6% (n=50) 11.6% (n=5) n/a 43.0% (n=55) 
N/a 4.5% (n=3) 32.6% (n=14) n/a 13.3% (n=17) 
Previous Genetic Education 
None 6.0% (n=4) 20.9% (n=9) n/a 10.2% (n=13) 
Biology Course 52.2% (n=35) 48.8% (n=21) n/a 43.8% (n=56) 
Specific Course on 
Genetics 




1.5% (n=1) 2.3% (n=1) n/a 1.6% (n=2) 
3.3.1.2 Knowledge of Genetics and Pharmacogenomics 
Efficacy evaluation of the FMR and ACCOUNT programs focused on analysis of the 
knowledge question responses to first ensure that these programs had significant impacts on 
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participant knowledge. The knowledge assessment was divided into two parts: self-assessment of 
genetics knowledge and true/false genetics quiz questions.  
The self-assessment of genetics knowledge analysis compared the participants reported 
level of understanding on a scale of one to five (1=no knowledge; 2=minimal understanding; 
3=moderate understanding; 4=above average understanding; 5=expert understanding) for the 
independent pre- and post-course survey responses. Analysis of the FMR participant data shows 
that average comfort level for the topic areas of pharmacogenomics (p=0.025), genetics of complex 
disease (p=0.022), and precision medicine (p=0.001) increased significantly but did not for basic 
genetic principles (p=0.108). Similar results were found when analyzing ACCOUNT provider 
participant data, showing that average comfort level for the topic areas of pharmacogenomics 
(p=<0.001), genetics of complex disease (p=<0.001), and precision medicine (p=<0.001) increased 
significantly but did not for basic genetic principles (p=0.781). Analysis of community member 
data showed that average comfort level for the topic areas of understanding of the concept of 
pharmacogenomics (p=<0.001) and precision medicine (p=<0.001) both increased significantly.  
The true/false genetics quiz question knowledge analysis compared mean knowledge score 
for pre- and post-course surveys. Since the pre- and post-course surveys were not linked, individual 
participant score increases could not be evaluated. Each survey included questions that were 
unique to the population being surveyed since each population received educational materials 
targeted to them. Some of the survey questions were the same but some were not. All questions 
that were used had been previously validated to show participant genetic knowledge and can be 
found in the surveys included in Appendix B. Mean knowledge score is based on the number of 
true and false questions answered correctly out of the 11 questions in the FMR program survey. 
The average score for pre-course participants was 8.57 (77.9%) and 9.60 (87.2%) for post-course 
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participants. Statistical analysis for the FMR program showed a significant increase in knowledge 
for participants (p=0.006) as shown in Table 4. 
Table 4: Statistical analysis of provider knowledge scores in the FMR Program 
Provider Analysis Mean Knowledge Score out of 11 questions p-value 
Pre-course 8.57 0.006 
Post-course 9.60  
 
Mean knowledge score is based on the number of true and false questions answered 
correctly out of the 14 questions in the ACCOUNT provider program survey. The average score 
for pre-course participants was 9.00 (64.3%) and 11.04 (78.9%) for post-course participants. 
Statistical analysis for the ACCOUNT provider participants showed a significant increase in 
knowledge (p=<0.001) as shown in Table 5. 
Table 5: Statistical analysis of provider knowledge scores in the ACCOUNT Program 
Provider Analysis Mean Knowledge Score out of 14 questions p-value 
Pre-course 9.00 <0.0001 
Post-course 11.04  
 
Mean knowledge score is based on the number of true and false questions answered 
correctly out of the 7 questions in the ACCOUNT community program survey. The average score 
for pre-course participants was 4.11 (58.7%) and 5.375 (76.9%) for post-course participants. 
Statistical analysis was also significant for an increase in knowledge in community members 
(p=0.003) as shown in Table 6.  
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Table 6: Statistical analysis of community member knowledge scores in the ACCOUNT Program 
Community Member Analysis Mean Knowledge Score out of 7 questions p-value 
Pre-course 4.111 0.003 
Post-course 5.375  
 
This analysis confirms a significant impact on provider participant knowledge for both the 
ACCOUNT and FMR programs but shows area for improvement for evaluation materials for both 
providers and non-providers.  
3.3.1.3 Attitudes/Perceptions Regarding the Use of Pharmacogenomics and Precision 
Medicine 
Attitudes and perceptions of participants of the FMR and ACCOUNT programs focused 
on multiple choice questions where participants could indicate their preference or plans as 
participants as well as questions ranking their attitudes towards specific genetic tests. The 
preference question analysis includes the potential answers participants could indicate and was 
different for each question. Specific answer options for these questions are included in the analysis 
below. For the questions concerning participants attitudes and perceptions towards testing options 
and provider knowledge, the research team focused on four broad categories of testing: 
pharmacogenomics, prenatal carrier, cancer risk, and direct to consumer testing. For the questions 
indicating participant perceptions of clinical utility, the responses participants could choose 
included 1=none, 2=minimal, 3=moderate, and 4=very useful. For the questions indicating 
participant perceptions of provider preparedness, the responses participants could choose included 
1=none, 2=minimal, 3=moderate, 4=above average, and 5=expert. For the questions indicating 
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participant perceptions of general statements, the responses participants could choose included 
1=strongly disagree, 2=disagree, 3=neutral, 4=agree, and 5=strongly agree. 
For initial preference analysis, almost all respondents for both FMR and ACCOUNT 
programs, except for 3 pre-course survey respondents for the FMR program, indicated they would 
benefit from additional education/training in genomic medicine. Additionally, provider 
participants for both programs were surveyed on their preferred mode of learning about medical 
genetics. The results of this are shown below in Figure 1. While the highest number of participants 
indicated a preference for in-person CME learning, the second most preferred mode of learning 
was online CME learning. 
 
 
Figure 1: Preferred mode of learning about genomic medicine indicated by provider participants of the FMR 
and ACCOUNT programs 
For the FMR program, 66% of pre-course survey respondents indicated they had undergone 
personal genetic testing (PGT) as part of the educational program, with 34% of survey respondents 
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choosing to utilize deidentified, random genetic data. The ratio of respondents indicating they had 
undergone PGT to respondents indicating they had not remained the same for the post-course 
survey. For the ACCOUNT program, 70.6% of pre-course community respondents and 69% of 
pre-course healthcare provider respondents indicated they had undergone PGT as part of the 
educational program, with 29.4% and 31% of each group choosing to utilize deidentified, random 
genetic data respectively. The ratio of respondents indicating they had undergone PGT to 
respondents indicating they had not changed drastically for both provider and community 
respondents. For ACCOUNT provider post-course respondents, only 41.4% had indicated they 
had undergone PGT and 58.6% indicated they had not. For ACCOUNT community post-course 
respondents, only 25% had indicated they had undergone PGT and 75% indicated they had not. 
The results of this question analysis are outlined below in Table 7. This allowed for data analysis 
of participant data from both participatory and non-participatory survey respondents in populations 
with a majority of participatory respondents and also non-participatory respondents. 
Table 7: Percentage of respondent groups for pre- and post-survey indicating they had undergone PGT as 
part of the course 
 FMR Program ACCOUNT Provider ACCOUNT Community 
Pre Post Pre Post Pre Post 
Yes 66% 67% 69% 41.4% 70.6% 25% 
No 34% 33% 31% 58.6% 29.4% 75% 
  
Analysis of pre- and post-course surveys from the FMR program show that there was no 
significant change in participant attitudes about the clinical utility of DTC, cancer carrier, prenatal 
carrier, and pharmacogenetic testing. Upon further analysis, both the pre- and post-surveys showed 
a high response of “moderately useful” for all types of testing surveyed about, with a noted absence 
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of any participants indicating they felt that any of the testing types were not useful at all (Figure 2 
and 3). This was found for ACCOUNT provider participants as well. 
 
Figure 2: Percentage of pre-survey responses indicating perceived utility of different genetic test types 
    
Figure 3: Percentage of post-survey responses indicating perceived utility of different genetic test types 
Similar results were noted for pre- and post-course survey analysis of the questions “most 
primary care physicians have enough knowledge to help individuals interpret the results of the 
testing options listed” and “most primary care physicians have enough knowledge to ensure 
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patients understand the risks and benefits surrounding the testing options listed”. These questions 
asked participants to report their perception of provider preparedness on a 5-point Likert scale. 
The majority of participants indicated the response “disagree” or “neutral” for both the pre- and 
post-course surveys for both questions with no significant change.  
 
Figure 4: Pre-survey responses indicating perceived knowledge of the general PCP population to interpret 
results for different genetic test types by response option 
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Figure 5: Post-survey responses indicating perceived knowledge of the general PCP population to interpret 
results for different genetic test types by response option 
 
Figure 6: Pre-survey responses indicating perceived knowledge of the general PCP population to understand 
risks and benefits for different genetic test types by response option 
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Figure 7: Post-survey responses indicating perceived knowledge of the general PCP population to understand 
risks and benefits for different genetic test types by response option 
Similarly, there was no significant change in participants perception of the general public’s 
ability to accurately interpret their PGT results, with the majority of participants disagreeing with 
this statement both before and after completing the FMR or ACCOUNT educational program. 
There was also no significant change for this question for ACCOUNT community members, with 
the majority disagreeing or remaining neutral with this statement both before and after the 
educational program. 
Additionally, a significant increase (p=0.018) was found between FMR pre- and post-
course surveys for the participants comfort in discussing genetics in general with patients. This 
question was not included in the ACCOUNT provider survey and could not be assessed. 
ACCOUNT community members indicated no significant increase in their comfort level 
discussing genetics in general with their primary care provider.  
With the increase in consumer utilization of PGT, providers were also surveyed on their 
awareness of direct-to-consumer testing. Only 85.7% of FMR provider participants indicated they 
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were previously aware of direct-to-consumer testing, which increased to 100% after this course 
due to the participatory nature of the educational program. Providers were then surveyed on if they 
had ever had a patient bring a genetic test result to them, though there was not an option to clarify 
what kind of genetic test result had been brought by the patient. While the majority of participants 
indicated that they had not had a patient bring genetic results to them, 20-30% of FMR participants 
and approximately 16% of ACCOUNT providers indicated that a patient had brought in genetic 
results into their clinical practice (Table 8). 
Table 8: Percentage of providers that have had patients bring a genetic test result to them in their clinical 
practice 
 FMR providers ACCOUNT providers 
Pre (n=65) Pre (n=43) 
Yes 21.5% (n=14) 16.3% (n=7) 
No 73.8% (n=48) 83.7% (n=36) 
 
In addition to provider awareness of DTC-GT, provider experience ordering or using 
different genetic testing modalities to manage their patients was surveyed. While the largest 
proportion of respondents for both FMR and ACCOUNT pre- and post-course surveys indicated 
that this question was not applicable to them, many others indicated having used a genetic testing 
method for patient management. Respondents were allowed to pick more than one option if 
applicable and not every respondent answered the question. Both pre- and post-course surveys 
were evaluated since participants could have had additional experiences between the 
administration of the pre- and post-course surveys. The most commonly reported technologies 
ordered or used across all groups was karyotype, with single gene tests as the second most 
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indicated technology (Table 9). Multi-gene panels and microarray were equally indicated with 
targeted sequencing and whole exome/genome sequencing having the least reports (Table 9). 
Table 9: Percentage of reported testing technologies ordered or used by provider participants to manage their 
patients 
 FMR providers ACCOUNT providers 
Pre (n=65) Pre (n=43) 
Not applicable 50.8% (n=33) 69.8% (n=30) 
Karyotyping 15.4% (n=10) 11.6% (n=5) 
Single gene tests 15.4% (n=10) 2.3% (n=1) 
Multiple gene panels 7.7% (n=5) 7.0% (n=3) 
Microarray  6.2 (n=4) 7.0% (n=3) 
Targeted sequencing 0% (n=0) 0% (n=0) 
Whole genome or exome 
sequencing 
1.5% (n=1) 2.3% (n=1) 
Not sure of the type 15.4% (n=10) 7.0% (n=3) 
 
Comparatively, ACCOUNT community participants were surveyed on the technologies 
that had been offered to them as part of their clinical care. The options for community members 
were very different from the options for providers and surveyed about pharmacogenomics, 
diagnostic, carrier, or cancer risk genetic testing offered to participants in their care. Responses 
showed no clear genetic technology was used significantly more than the others, showing no 
inclination towards or familiarity with one testing type over another. However, there was a 
difference between testing technologies indicated in the pre- and post-survey. This difference 
could be due to multiple reasons but since the answers are not linked the specific participant 
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changes could not be tracked. A likely cause is that participants were not aware they had genetic 
testing or what type it was until after the educational course, but we cannot know for sure. 
Table 10: Percentage of reported testing technologies offered to community member participants 
 ACCOUNT community members 
Pre (n=19) 
Pharmacogenomics 26.3% (n=5) 
Diagnostic genetic testing 5.3% (n=1) 
Carrier testing 5.3% (n=1) 
Genetic cancer risk testing 26.3% (n=5) 
 
In the post-course FMR program survey, respondents were asked about which specific 
aspects of the program they found to be valuable in their learning experience. The specific aspects 
that participants could indicate their attitudes towards on a 5-point Likert scale were the online 
courses, the live course, the Test2Learn exercises in the live course, the optional reading material, 
the clear learning objectives, the detailed course outlines, and the interactive exercises in the live 
course. The majority of participants indicated “neutral” for all aspects. 
3.3.2  Curriculum Development 
During initial literature reviews, 592 abstracts were identified and 63 were reviewed in 
PubMed/Embase which identified three WGS education programs. Eight additional programs 
were found through NHGRI’s G2C2 and internet queries. Of these programs, eight provided web-
based instruction and one program incorporated analysis of personal genomic testing into a health 
sciences curriculum to increase student learner engagement and enhance understanding. Audiences 
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were composed of students, residents, and health care professionals with common topics including 
ethical, legal, and social implications (ELSI); testing technologies; WGS in various diagnostic 
contexts; and genomics communication. No courses for KOLs were found. Gaps included 
addressing infrastructure needs and processes surrounding clinical genomic testing, which 
reinforce the need for participatory educational programs for front-line clinicians and KOLs.  
 
Figure 8: Literature review process for curriculum development 
The multidisciplinary team developed eight topics areas for clinicians (e.g., ordering WGS, 
returning of WGS results, WGS and the patient health record, ELSI) and six topic areas for KOLs 
(e.g., economics, data warehouses and enterprise infrastructure, ELSI).  
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Figure 9: Results of literature review analysis for curriculum development 
Within these topics and tailored per audience, a total of 52 unique learning objectives have 
been constructed between clinician and KOL participants. Knowledge, comfort level, and practice 
behavior outcomes will be evaluated as important general goals for participants. Learning 
objectives were created to meet AAFP and G2C2 genomic learning competencies. The drafted 
curriculum for the healthcare provider participants is shown below in Table 11 
Table 11: Learning objectives sorted by topic area created for clinician participants of the MWGS program 
Why the excitement around whole genome sequencing and precision medicine? 
1. Describe innovations in genetic technologies that have advanced scientific knowledge 
towards precision medicine. 
2. Differentiate between different genetic testing technologies. 
3. Recognize logistical, ethical, legal, and societal issues that impact genetic testing and data 
use in the healthcare setting. 
Basic genetics concepts 
1. Define foundational genetics concepts and nomenclature.  
2. Describe mechanisms of genetic variation that can lead to disease and differences in 
treatment response. 
3. Differentiate between the clinical diagnosis of disease informed by genetics and the 
identification of genetic predisposition to disease.  
4. Identify the relevance of genetics in the manifestation and treatment of disease. 
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5. Recognize the combined impact of behavioral, social, environmental, and genetic factors in 
the manifestation, prevention, and treatment of disease.   
Advanced genetics concepts 
1. Compare preemptive versus reactive testing. 
2. Identify when genetics is relevant to your practice 
3. Explain challenge the uncertainly and evolving knowledge associated with interpretation of 
certain results.  (e.g. VUS, reclassification) 
4. Defend the opportunity to make decisions regarding the return of results as opposed to 
mandatory return 
Application of WGS in practice 
1. Explain leading applications for WGS in: 
- Undiagnosed disease in critically ill infants 
- PGx 
- Cancer risk assessment and diagnosis 
- Complex disease 
- Solving diagnostic odyssey  
2. Determine which genetic testing technology is most appropriate.  
3. Review core concepts in the interpretation WGS results. 
Ordering at WGS   
1. Identify considerations for selecting a genetic testing laboratory from which to order a test. 
2. Develop procedures for appropriate consenting for WGS. 
3. Discuss the potential impact of secondary findings in genetic testing. 
4. Evaluate the value of WGS testing in a treatment plan for an individual patient. 
5. Develop a process to estimate the cost of WGS services in the current reimbursement 
landscape 
Returning of WGS results 
1. Assess the source of existing test results (e.g., CAP/CLIA, clinical, vs. direct-to-consumer, 
research results) and recommend new testing if appropriate. 
2. Explain the differences between an informative/noninformative results and issues 
surrounding evolving knowledge. 
3. Identify reliable online resources of genetic information for providers, patients, and those 
whom patients choose to share information. 
4. Use a culturally sensitive approach to patient counseling regarding test results. 
5. Identify when and how to refer a patient to a genetic specialist. 
WGS, the patient health record, and EHRs 
1.  Describe best practices proper documentation of test results in patient heath record. 
2. Identify challenges associated with the integration of genomic data in the EHR.  
3. Describe the benefits of integrated clinical decision support in the EHR.   
4. Summarize the need for re-classification of genetic test results based on updated knowledge.  
Ethical, legal, and societal implications 
1. Explain ethical reasons to protect privacy of genetic data.  
2. Discuss duty to inform  
3. Describe the ethical considerations regarding genetic testing under the age of 18.   
4. Recognize the legal protections against discrimination based on genetic test results (e.g., the 
Genetic Information Nondiscrimination Act of 2008).  
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Additionally, the learning objectives for the KOL participants is shown below in Table 12. 
Table 12: Learning objectives sorted by topic area created for key opinion leader participants of the MWGS 
program 
Why the excitement around precision medicine and whole genome sequencing? 
1.       Describe innovations in genetic technologies that have advanced scientific knowledge 
towards precision medicine. 
2.       Differentiate between different genetic testing technologies. 
3.       Explain the value of testing as a screening and prevention strategy to improve clinical 
outcomes at decreased cost. 
4.       Recognize logistical, ethical, legal, and societal issues that impact genetic testing and 
data use in the healthcare setting. 
Key genetics concepts 
1.       Define foundational genetics concepts and nomenclature.  
2.       Describe mechanisms of genetic variation that can lead to disease and differences in 
treatment response. 
3.       Differentiate between the clinical diagnosis of disease informed by genetics and the 
identification of genetic predisposition to disease.  
4.       Identify the relevance of genetics in the manifestation and treatment of disease. 
5.       Recognize the combined impact of behavioral, social, environmental, and genetic factors 
in the manifestation, prevention, and treatment of disease.   
Leading application of WGS in the healthcare settings 
1.       Describe leading scenarios where whole genome sequencing is having a profound impact 
on healthcare.  
a.       Undiagnosed disease in critically ill infants 
b.       PGx 
c.       Cancer risk assessment 
d.       Complex disease  
e.       Solving diagnostic odyssey  
2.       Distinguish up and coming applications for the use of WGS data 
Economics [payors/reimbursements/cost savings] 
1. Explain the cost, cost–effectiveness and reimbursement by insurers relevant to genomic 
tests and test interpretation for patients and populations. 
2. Needs for policy (WGS/WES) 
3. Cost of diagnostic odyssey vs WGS 
4. Implications for IDFS/vertical vs others 
Data warehouses, enterprise infrastructure for testing, data storage, and return of results 
1. Describe the rationale for a having a genomics data strategy (e.g. from CCM report) 
2.       Describe best practices proper documentation of test results in patient heath record. 
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a.       Describe the institutional policies that govern what results it is permissible or obligatory 
to place in the EHR. 
b.       Explain the implications, including benefits and downsides, of results being placed in the 
health record, particularly EHRs. 
3.       Identify challenges associated with the integration of genomic data in the EHR. 
a.       Privacy/security, size/amount/organization of data 
4.       Describe the benefits of integrated clinical decision support in the EHR.  
5.       Summarize the need for reclassification of genetic test results based on updated 
knowledge. 
Ethical, legal, and societal implications 
1.       Explain ethical reasons to protect privacy of genetic data. 
2.       Examine core concepts in ethics surrounding WGS including the discuss duty to inform, 
legal protections against discrimination based on genetic test results (e.g., the Genetic 
Information Nondiscrimination Act of 2008, state laws), and genetic testing under the age of 
18.  
3.       Recognize the increased liability that accompanies access to detailed genomic patient 
information and maintaining confidentiality and security. 
 
3.4 Discussion 
Analysis of previous genetics programs on the Test2Learn platform immediately showed 
how important it is to encourage or incentivize participants to complete both pre- and post-course 
evaluation and to have a reliable linkage system for participants. Having a larger population of 
respondents adds power to the data analysis and linkage adds the ability to pair the pre- and post-
course data. Linkage allows for more robust statistical analysis and the ability to track individual 
improvement with the nuance of the demographic questions. Examples include being able to 
analyze if knowledge or comfort improvements were correlated with participant age or ethnicity, 
especially in the field of genetics where patient ethnicity can impact the informed consent process 
for testing. Linkage also allows for comparison of knowledge increases in participants that chose 
to undergo PGT as part of the course and those that chose to utilize random deidentified data to 
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further analyze the impacts of participatory education on learner knowledge. This combination of 
participatory and non-participatory program participants is expected with the MWGS program so 
comparison of these two groups also impacts curriculum and evaluation development. 
Curriculum development started with intensive literature reviews that identified 592 
abstracts related to the MWGS program that were reduced to 63 abstracts reviewed to find articles 
relevant to the program for in-depth review. The absence of any educational programs for KOLs 
emphasized the education gap this program could help fill, as most insurance approvals for genetic 
testing do not occur in a vacuum. KOL education is just as important as provider education to help 
get genetic care covered and made accessible to the general population and not just an affluent 
subset that has the means to pursue testing without the aid of insurance. Additional education gaps 
were found in current educational programs for providers concerning infrastructure needs of WGS 
and the processes surrounding clinical genomic testing. These identified gaps influenced the 
learning objectives associated with WGS result needs, genomic testing processes, and ELSI issues 
associated with WGS. Based on the competencies identified by AAFP in genomic medicine, prior 
genetic educational experiences of multidisciplinary teams’ members, and identified gaps in 
current education, eight topic areas were identified for providers and six topic areas were identified 
for KOLs. Within each audience and topic area, 52 unique learning objectives were drafted for the 
educational program. The creation of certain learning objectives was influenced by the data 
analysis from previous programs. 
The demographics of provider participants were fairly consistent with a recent publication 
of the demographics of Primary Care Physicians by the Robert Graham Center that reported a 
different ratio of male to female providers in primary care [58]. This report showed the vast 
majority of PCPs are MDs (not a fellow or resident) over the age of 35 while the provider 
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participants of these programs were primarily reported to be younger than the age of 35 and also 
physician residents. This discrepancy is due to the targeting of the resident population for the FMR 
education program and would also be why the majority of provider participants reported 
completing their advanced degree after 2011. This report also showed a slight majority of males 
to females (55% to 45%) while respondents of the FMR and ACCOUNT programs showed a slight 
majority of females to males (64% to 36%) which may also be due to the younger population 
included in this analysis. Even with differences in the reported average demographics of the PCP 
population and demographics of participants included in this analysis, the information gathered 
from this analysis is likely to be applicable to the population expected to enroll in the MWGS 
educational program. Despite the younger, more recently graduated population included in this 
analysis, the majority of providers indicated the highest level of genetics education they had 
received was a biology course. This confirmed previously cited reports that medical students, even 
those that have recently graduated, have not had specific course on genetics and therefore not 
receiving the robust education needed to integrate genetics into clinical care, further reinforcing 
the need for education on the integration of genetic testing results into clinical care. Later in the 
survey, a vast majority of participants also indicated they would benefit from additional 
education/training in genomic medicine, presumably seeing the clinical applications of genetics in 
their clinical practice as well as the gap in their education. Provider participants were additionally 
surveyed on their preferred mode of learning. While the highest number of participants indicated 
a preference for in-person CME learning, this kind of learning mode is not always widely 
accessible, especially in the era of COVID-19 precautions and travel restrictions. The second most 
preferred mode of learning was online CME learning, which supports the creation of a web-based 
educational program about genomic medicine, both due to provider preference and also the ability 
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of online education to be more accessible, regardless of location, for those interested in further 
genomic medicine education.  
Additionally, this analysis identified gaps in areas to gather demographics on participants 
to further evaluate the MWGS educational program. Areas include participant ethnicity, previous 
genetic education, and years of experience in current position indicated for all participants. 
Ethnicity was previously only included for community participants and previous genetic education 
was only included for provider participants. Years of experience in current position indicated 
would help distinguish amount of experience in current position for all participants regardless of 
current position. 
Knowledge was evaluated both with participants reporting perceived knowledge of specific 
subjects on a 5-point Likert scale and a true/false genetics knowledge quiz. Not all of the subjects 
included for each program were relevant to the MWGS program and not all of the subjects were 
the same for each of the participant groups, so they were not analyzed for this project. The topic 
areas of basic genetic principles and genetics of complex disease were not included in the 
ACCOUNT community surveys because increase in knowledge in these areas was not a goal for 
the community members. Due to this, analysis was focused on provider participant perceived 
knowledge of basic genetic concepts and genetics of complex disease, and all participant perceived 
knowledge of pharmacogenomics and precision medicine. These topic areas overlapped 
significantly with the topic areas chosen to focus on for the MWGS. Pharmacogenomics is a topic 
area that greatly relates to WGS data since PGx results are commonly included in WGS data so 
education on the clinical applications of these results will be included in the curriculum. Participant 
perceived knowledge was shown to increase for both pharmacogenomics and precision medicine 
for all participants, and provider perceived knowledge of genetics of complex disease. Provider 
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perceived knowledge of basic genetic concepts was not found to be significantly increased but this 
was because providers indicated they had a moderate to above average knowledge of basic genetic 
concepts both before and after completing the educational programs. 
Due to this finding, the multidisciplinary team could plan to spend less time focusing on 
basic genetics concepts and have a more focused curriculum since this population has been shown 
to have adequate perceived knowledge of this topic area. Time spent focusing on a topic that a 
participant feels they already have a high level of knowledge in must be balanced to help build 
participant confidence and also challenge them appropriately. Another adaptation discussed was 
to intersperse the basic genetics concepts throughout the curriculum in topic areas that will utilize 
the concept in an application, a higher level of learning to further challenge participants and start 
topic explanation from areas of previous understanding.  
The general ability of the FMR and ACCOUNT programs to significantly increase 
participant knowledge was seen for all three participant groups. Quiz questions for each participant 
group was specific to the information being assessed by the research team. The exact questions 
asked of each group can be referenced in Appendix B but were all drawn from the same pool of 
questions that had been systematically validated to evaluate learner knowledge of genetics. The 
questions used for the knowledge evaluation will be adapted for the MWGS education program 
because, while systematically validated, these questions do not show targeted evaluation of 
participant knowledge of the topic areas covered by this program. Also, as previously described in 
the literature, it is important to ask a minimum number of complex questions to test participant 
knowledge. Due to this, the knowledge questions will be updated to evaluate key takeaways for 
the specific topic areas selected by the multidisciplinary team.  
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The attitudes of participants on different topics were also assessed with a 4 point Likert 
scale. One question analyzed was aimed at identifying providers attitudes about the clinical utility 
of DTC, cancer carrier, prenatal carrier, and pharmacogenomic testing. Analysis showed that the 
course had no impact on provider attitudes about the utility of specific genetic tests, with the 
majority of participants finding the different testing options to be moderately useful before and 
after the educational program. This finding aligns with the programs goal to educate on effective 
clinical applications of genetics in medicine, not to promote the use of genetic testing regardless 
of patient presentation. Additionally, none of the participants indicated that the different genetic 
testing options were not useful at all to them clinically. This could potentially be because 
participants had been educated on potential clinical applications of the genetic testing options 
surveyed and believed that all of the testing options have some clinical use. This finding could also 
be due to post-course response bias. This further emphasizes the importance of linking data for the 
MWGS educational program from the pre- and post-course surveys and to continue to provide 
unbiased education on the use of WGS in clinical care.  
Additionally, the perceptions of participants on different topics were also assessed with a 
5-point Likert scale. Perceptions of provider participants on general provider preparedness to help 
individuals interpret their results and help patients understand the risks and benefits of the same 
testing options were analyzed. The results of this analysis showed similar, unaffected pre- and 
post-course results as previously mentioned with the majority of participants disagreeing that 
providers are adequately prepared. This shows that the course did not endorse provider 
preparedness being either adequate or inadequate. To assess participant perceived comfort levels 
speaking with patients about genetics, statistical analysis was completed and showed significant 
increase in participant comfort after completing the course. This supports that genomic education 
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can increase provider comfort in discussing genetics in general with patients and when paired with 
the significant increase in participant genetics knowledge, can help endorse accurate discourse 
with patients about genetic applications in their clinical care. This supports that participant comfort 
levels discussing genetics can be impacted by education and should be a focused topic area for the 
MWGS program curriculum. A main goal of this program is to educate on the clinical applications 
of WGS results in clinical care which has been emphasized in the curriculum, which can include 
results that impact medical management in many ways that should be discussed with patients.  
It is also important to evaluate if provider participants have had patients bring genetics 
testing results into them and what types of genetic technologies they had ordered or used personally 
in their clinical practice. About 20-30% of FMR participants and approximately 16% of 
ACCOUNT providers indicated that a patient had brought in genetic results in their clinical 
practice, but the specific type of result brought in was not surveyed. Due to this, this analysis did 
not influence what types of genetic results are reviewed with provider participants but did 
influence the creation of learning objectives related to benefits and limitations of genetic results 
brought in by patients. The MWGS research team also identified the importance of reviewing the 
similarities and differences between different genetic testing technologies and the benefits and 
limitations of the results. Currently, WGS is almost exclusively utilized in research so very few 
provider participants were expected to have experience with ordering or using these results, which 
is what the survey found. The survey also confirmed that many participants did not indicate having 
utilized genetic technologies in their clinical practice, potentially due to their acknowledgment in 
their knowledge gap in genomic medicine or the inability to recognize clinical applications of 
different testing options. This survey also identified that karyotyping was the most commonly 
utilized technology, with single gene tests as the second most common and multi-gene tests and 
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microarrays both indicated as the third most common genetic tests utilized. This finding reinforces 
the need to review the similarities and differences between the test they are more familiar with 
than WGS. ACCOUNT community members were surveyed on testing technologies they have had 
been offered in their clinical care. Responses showed no clear genetic technology was used 
significantly more than the others, showing no inclination towards one testing type which may 
represent an “as indicated” clinical approach for all of their care and not provider preference and/or 
comfort with one type of test results regardless of patient presentation.  
In the post-course FMR program survey, participants were asked about which specific 
aspects of the program they found to be valuable in their learning experience. This section utilized 
an entire page of the survey and was included at the end so the overwhelming “neutral” responses 
for every aspect surveyed may have been heavily influenced by survey fatigue. 
3.4.1  Limitations 
Analysis of the survey data collected from the ACCOUNT and FMR programs was limited 
by the small number of participants, inability to pair the data, and uneven amount of pre- and post-
course surveys completed. Analysis of pre- and post-course surveys was also limited because the 
anonymous identifier created by participants was not successfully collected for all pre- and post-
course responses, resulting in the inability to track individual progress. Due to this, evaluation of 
knowledge gain after the program intervention was focused on overall score change. This 




Few WGS training programs exist for clinicians, and none exist for KOLs. The MWGS 
educational program is necessary to fill educational gaps and prepare clinicians for the integration 
of clinical genomic sequencing results into clinical care. Current educational programs that attempt 
to address clinical genomic sequencing used variable educational engagement methods. Although 
participatory education has perceived value as a method for genomics education, it is underutilized. 
With collaboration amongst a multidisciplinary team, we plan to expand the Test2Learn program 
using the new topics and learning objectives to develop web-based, participatory education 
program on WGS and its clinical applications. Analysis of previous genetic education programs 
that utilized the Test2Learn platform and current literature is necessary to create an informative, 
accurate, and novel curriculum on genomic data usage in clinical care. Lessons learned from 
previous programs are vital in shaping the evolving curriculum for the MWGS educational 
program. Multidisciplinary input is also necessary to create a robust curriculum that maximizes 
participant benefit and minimizes participant harm, especially in the context of a participatory 
program.  
The efficacy and significance of the MWGS educational program will not be assessed until 
the program is launched in September 2021. Effective evaluation of this program is imperative to 
identify areas of strength and opportunities for improvement. Evaluation of the novel educational 
program with a participatory aspect is also imperative as this educational method is used more. 
Evaluation tool formation for the MWGS is also heavily influenced by analysis of previous survey 
materials and should be done with multidisciplinary input.  
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4.0 Relevance to Genetic Counseling and Public Health Genetics 
Clinical genetic testing continues to become more advanced and complicated as testing 
techniques improve. It also continues to become more accessible as testing becomes more cost 
effective. During the Human Genome Project, sequencing the human genome using Sanger 
sequencing took over 10 years and cost almost $3 billion [59]. NGS has revolutionized the 
diagnostic process as a reliable, quick, and relatively cheap sequencing technique with the cost of 
sequencing a human genome dropping below $1,000 as of 2020 [60, 61]. With advancing 
technology and increasing access, education for health care providers is essential.   
Education is imperative to the development of policies and the foundation of clinical 
practice. Education is also encompassed in many of the ten essential public health services such as 
effective communication, assuring a competent workforce, and linking to/providing care. In order 
to provide appropriate care and meet the growing need for genetics services, non-genetics 
clinicians will need to be educated on genetic testing and how to interpret genetic information.  
These clinicians also need to understand that genetic testing is not always the appropriate next step 
in medical management and must be able to identify when genetic testing may actually be 
indicated. Previous studies have exposed the potential harm that undereducated providers ordering 
genetic testing can cause, showing the need for an effective educational program on clinical utility 
of genetics and genomics for non-genetics providers. (cite) 
In support of the critical need for genetic education, the NSGC states its commitment to 
“advance the various roles of genetic counselors in health care by fostering education, research, 
and public policy to ensure the availability of quality genetics services”. Five different Medical 
Schools in the US have created and implemented participatory medical and graduate medical 
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genetic education courses: Temple University, Stanford University, Tufts University, Mt. Sinai, 
and University of Pittsburgh, as well as the University of Pittsburgh’s School of Pharmacy [12, 
62]. Genetic counselors are often involved in these courses; three of the five universities - Stanford 
University, Mt. Sinai, and University of Pittsburgh - have an accredited genetic counseling 
program where students and/or faculty have involvement with the course [12, 44, 50]. This 
relationship shows that when formulating the curriculum of a genetics educational program, 
genetic counselors and public health professionals are important stakeholders of the project as 
content experts as well as patient and public advocates. 
As WGS becomes more common, more clinicians will encounter genetics results and 
applications in clinical care and need genetic education to help them understand how to integrate 
genetics into their practice. While the use of WGS in patient care is exceedingly rare currently due 
to limited insurance coverage, limited number of labs that perform WGS, and limited 
understanding of the clinical utility of WGS, it is anticipated that its use will grow. By utilizing 
WGS in a participatory course,  clinicians can be educated on the most advanced technology 
available as it begins to be used more often in clinical care. By creating educational programs 
around ethical and informed genetic data use and application, programs like the MWGS program 
will become a bridge between genetics professionals and non-genetics clinicians.  
An important component of participatory education courses is the process of and education 
about informed consent.  Previous attempts to include a participatory aspect in genetic education 
exposed the potential for harm to participants who have testing without proper informed consent. 
This process further helps to emphasize participant understanding of the consent process and its 
nuances by undergoing a similar process themselves. While not every person may be interested in 
submitting a personal sample as part of the course, the course can still be helpful even if an 
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individual elects to use an anonymized sample. Thus,  informed consent for participants is crucial 
so each individual can make an informed choice about undergoing analysis as part of the course, 
especially with the complexity of genetic testing results.  By involving a multidisciplinary team 
including ethicists and genetics professionals, this potential harm to participants can be minimized 
while emphasizing participant educational benefit. 
Genetic testing results have many different impacts and have implications throughout 
healthcare and the stages of life. For clinicians, participatory education programs can help them 
understand different types of testing and the different types of results they can receive that will 
impact patient care. As the application of genetics continues to transition from purely research to 
clinical offerings, it is important to emphasize to non-genetics providers the potential benefits and 
harms of genetic testing. 
An essential aspect of public health is the continued effort to provide equitable care, 
regardless of age, gender, race, or background, and this requires educating providers on how those 
differences may impact genetic results. Educational programs that are widely available can help 
educate more clinicians on genetics and increase availability of providers equipped to handle 
genetics. The MWGS program includes educational aspects on the way that patient background 
can impact results as well as subsequent care such as: 1) the integration of genetics and genomics 
in healthcare regardless of a patient’s background, 2) an emphasis throughout the curriculum on 
educating all participants on the effect that social determinants of health can have on patient 
populations and, 3) a section for providers on cultural informed care in genetics is imperative to 
continue advancing equitable care. These different applications and impacts of genetic test results 
are also important to emphasize to KOLs in the insurance provider industry. 
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As evidence to support clinical utility of WGS expands, insurance coverage and labs 
completing WGS will respond, potentially increasing coverage and availability of WGS [63]. 
Educating KOLs on the benefits and limitations can help encourage coverage and responsible 
adoption of WGS in clinical care. For KOLs, this can help emphasize the benefits and limitations 
of different genetic testing technologies and the positive impact of insurance coverage for different 
technologies. Insurance coverage can be a key deciding factor for most families when making 
healthcare decisions and can have a massive impact on patient outcomes.  
The need to assure the public of a competent workforce is another essential service of 
public health that this educational program can help fulfill through evaluation of previous 
programs. Further, evaluation is an important aspect of public health, as is learning from previous 
experiences in history. Analysis of previous course data helps identify opportunities to improve 
the MWGS program and build on previous successes. For example, the FMR and ACCOUNT 
programs showed many areas of improvement as well as success off which the MWGS could build. 
While the two populations being targeted for the MWGS program will receive education specific 
to their areas of impact, evaluation is a key component to assess the program’s ability to educate 
on the overlapping key topic areas.  
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5.0 Public Health Essay: Creation of Evaluation Tools for a Wed-Based, Participatory 
Education Program on Clinical Applications of Whole Genome Sequencing Utilizing 
Lessons Learned from Previous Participatory Genomics Courses 
5.1 Project Background 
The Mellon Whole Genome Sequencing Project (MWGS) is a web-based, participatory 
genomics course that will be created administered to both clinicians and key opinion leaders 
(KOLs) based on the curriculum previously described in this document. Current funding allows 
for 140 clinicians and KOLs who are ideally positioned to rapidly advance WGS use in clinical 
practice to take this course as a participatory participant. Participants will have the option of 
undergoing whole genome sequencing (WGS) and using their genetic data throughout the course.  
WGS data will be generated from participant samples that are submitted to the Institute of 
Precision Medicine. This data will be made available to participants on the Test2Learn platform 
for the participatory aspect of the course, and course material will be administered over Canvas. 
The recruitment for the pilot launch of this program is expected to be in September 2021 at the 
Precision Medicine World Conference (PMWC).  The logic model for this program is included 
below in Figure 6 and outlines the anticipated inputs, outputs, and outcomes of the MWGS project. 
The goal of the evaluation survey outlined in this paper is to evaluate the short term outcomes of 
this project, and additional surveys will be developed in the future to evaluate the medium and 
long term outcomes of this project. 
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Figure 10: Logic model for the MWGS project 
5.1.1  Project Aim: Survey Development 
Pre- and post-program surveys will be created to evaluate the effectiveness of the course 
as well as the participants’ attitudes and perceptions of precision medicine and medical genetics.  
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5.2 Development of Survey Design, Methods, and Topics 
5.2.1  Survey Design 
The evaluation surveys for the MWGS program were developed in Microsoft Word. While 
similar, separate surveys were developed for the clinician and KOL participants.  The clinician 
surveys included sections on demographics, knowledge of genetics and precision medicine, and 
attitudes and perceptions regarding the use of WGS and precision medicine in clinical care 
(Appendix C.1). The KOL’s surveys included sections on demographics, knowledge of genetics 
and pharmacogenomics, and attitudes and perceptions regarding the use of WGS and precision 
medicine in clinical care (Appendix C.2).  Responses will not be required for any individual 
questions, and respondents will be able to exit the survey at any time. The pre-course survey will 
be delivered with the course and the post-course survey will be collected once the course is 
completed. Demographics questions will be administered at the initial participant sign on and only 
asked once. Knowledge and attitudes/perceptions questions will be administered immediately 
before and after the course. This change was made from previous courses where all pre-course and 
post-course questions were completed in one large survey in hopes of breaking up the survey to 
decrease survey fatigue. 
5.2.2  Survey Development Methodology 
 The survey question pool was developed using previously validated questions from the 
FMR and ACCOUNT programs and adapting them for this course using lessons learned from 
previous analysis, information gathered during the literature review, and input from the research 
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team. The FMR survey used as the base for the clinician survey was 136 questions, and the 
ACCOUNT community survey used as the base for the KOLs survey was 108 questions. A copy 
of the clinician survey question pool is included in Appendix C.1 and is 91 questions in total. A 
copy of the KOLs survey question pool is included in Appendix C.2 and is 83 questions in total.  
5.2.2.1 Demographics 
As the survey for the MWGS program was created, demographics were kept uniform 
between populations and only included in the pre-course survey. This section included 15 
questions for both KOLs and clinician participants that were not expected to change during the 
duration of the course. This included demographics such as the participant’s gender, age, and 
position. Major changes from the survey of the previous programs include surveying all 
participants’ ethnicity, years of experience in their current position, and questions about whether 
participants submitted a DNA sample. Some questions were also moved from the attitudes and 
perceptions section into the demographics section, such as the question surveying if participants 
planned to undergo genetic testing as part of the course since the answers to these questions were 
not expected to change before and after taking the course. The full survey for both participant 
populations can be found and further reviewed in Appendix C. 
5.2.2.2 Evaluation of Participants Knowledge of Precision Medicine and Medical Genetics 
Evaluation of participants’ knowledge of precision medicine and medical genetics has been 
attempted before, both in the literature and in the previous Test2Learn programs. A literature 
review of current knowledge evaluation strategies was conducted and integrated into the 
knowledge-based questions from the FMR and ACCOUNT programs for the creation of the 
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knowledge evaluation questions for clinicians and KOLs who will participate in the MWGS 
program. 
Clinician Knowledge Question Development 
Previous medical education program evaluation approaches have been mostly quantitative, 
focusing on the pre- and post-course knowledge surveys as a barometer for program effectivity. 
While qualitative data provides deeper insight into participants’ perceptions and experiences, 
quantitative data is the most commonly utilized [64]. This is due to the limited time availability of 
medical students, medical providers, and KOLs. Evaluation of educational programs on their 
ability to significantly increase knowledge in a subject matter is essential to proving the utility of 
the program and for highlighting areas of the program that could be improved. Evaluation of 
efficacy of genetic educational programs has centered on the ability of participants to answer  
knowledge questions in both pre- and post-course surveys to compare genetic knowledge of 
participants before and after completing the educational program. 
Unfortunately, while working with graduate medical education and continuing medical 
education, case example questions have not been shown to be feasible, as many respondents will 
not take the time to read through and respond. Previous programs have also utilized true/false 
knowledge questions and still experienced minimal responses even with short questions. Low 
response rates on previous program post-course surveys has further prompted survey analysis for 
this program to try and maximize responses.  
The Bonham and Sellers Genetic Variation Knowledge Assessment Index (GKAI) was 
developed to understand physician knowledge of genomics concepts and was created as part of a 
cross-sectional study [65]. This scale was created and measured as a count of correct answers 
during a cross-sectional study surveying 787 general internists in the United States but was never 
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tested for use in a longitudinal study [65].This scale was used by Haga et. al. while surveying 
primary care physicians knowledge of personal genetic testing as a part of a longitudinal study [7]. 
Despite the reported increase in comfort discussing genetics, no significant change in knowledge 
was observed between pre- and post- testing, with the majority of participants answering five out 
of six questions correctly both pre and post-test, indicating the need for improvement of knowledge 
survey question efficacy [7].  
Many precision medicine research projects took a similar approach, creating multiple 
choice knowledge questions that are specific to the information presented in the program. For 
example, the MedSeq project mentions the use of a 6-item multiple choice survey created by their 
study team to analyze participant knowledge longitudinally [6]. This allows researchers to perform 
targeted evaluation on the knowledge they are hoping to impart on participants, focusing on 
analysis on key-takeaways that can be more succinct rather than in-depth application questions. 
The knowledge evaluation questions in the FMR and ACCOUNT programs focused on the 
understanding of general genetics concepts rather than the educational takeaways specific to those 
programs. As an educational class on genetics for physician residents, providers, and community 
members, general evaluation of genetic concept literacy was appropriate for course evaluation. 
However, because the MWGS is an educational program focused on clinical care and integration 
of genetic results into care, it is important to evaluate participant understanding of the information 
presented to them in the course. The 18 clinician knowledge questions developed using the lessons 
learned from the literature review and previous programs are included below in Table 13. The 
questions were organized by topic areas selected by the research team with one question 
representing each topic area and paired with the 5-point Likert scale knowledge self-assessment 
included in the survey. For each topic area, the curriculum related to the topic area was pulled into 
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the table and used by the research team to create consensus key-takeaways. For clinicians, this 
resulted in the creation of nine multiple choice questions meant to assess clinician participant 
knowledge on the topic area. The correct answer for each question is bolded. 
Table 13: Knowledge questions for clinicians paired with the topic area the question is evaluating, including 
topic key-takeaway and related curriculum 
a) Precision medicine None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
1. Precision medicine takes into account individual variability in the 
genome to personalize medical management. Common clinical 
applications of precision medicine include all of the following 
EXCEPT:  
 Use of pharmacogenomic (PGx) test results to target 
medication prescribing. 
 Use of polygenic risk scores (PRS) to assess a patient’s risk 
for common diseases. 
 Use of panel genetic testing to assess a patient’s risk for 
common cancers. 
 Use of carrier genetic testing to assess a patient’s risk of being 
a carrier for a rare disease. 
 Use of expansive genetic sequencing to assess a patient’s risk 
of having a genetic condition. 
Key takeaway Examples in current clinical care, as well as benefits and limitations of 
genetics and the promise of enabling individualized care with superior 
outcomes. 
Related curriculum Describe innovations in genetic technologies that have advanced 
scientific knowledge towards precision medicine. 
Recognize logistical, ethical, legal, and societal issues that impact 
genetic testing and data use in the healthcare setting. 
b) Whole genome 
sequencing 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
2. Whole genome sequencing cannot detect: 
 Single nucleotide variants (SNVs) 
 Large structural variants 
 Changes in methylation 
 Copy number variations 
 Mitochondrial DNA variants 
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Key takeaway Understand risks vs benefits and limitations, including technology 
differences between WGS and other genetic testing. 
Related curriculum Differentiate between different genetic testing technologies. 
Evaluate the value of WGS testing in a treatment plan for an individual 
patient. 
c) Basic genetic concepts  None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
3. Mutations are changes in an individual’s DNA and results in a 
different version of the gene. Which of the options below is an 
example of a mutation that, if considered independently, would not 
impact medical management? 
 A patient with one pathogenic mutation in CYP2C19. 
 A patient with Trisomy 21. 
 A patient with one pathogenic mutation in BRCA1. 
 A patient with one pathogenic mutation in CFTR. 
Key Takeaways Understand types of genetic variation and their nomenclature (Ex. 
SNP, PRS, etc). 
Related curriculum Define foundational genetics concepts and nomenclature.  
Describe mechanisms of genetic variation that can lead to disease and 
differences in treatment response. 
Differentiate between the clinical diagnosis of disease informed by 
genetics and the identification of genetic predisposition to disease.  
Identify the relevance of genetics in the manifestation and treatment of 
disease. 
Recognize the combined impact of behavioral, social, environmental, 
and genetic factors in the manifestation, prevention, and treatment of 
disease.   
d) Advanced genetic 
concepts 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
4. Genetic mutations are classified on a scale from benign to uncertain 
to pathogenic per ACMG-AMP guidelines. A patient has genetic 
results that report a variant of uncertain significance. Which of the 
following is not a possibility that should be discussed with the 
patient?: 
 As the lab gets more data, they reclassify the variant as benign. 
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 As the lab gets more data, they reclassify the variant as 
pathogenic. 
 In hopes of getting more data, the lab offers testing only for 
family members that are similarly affected to help 
reclassify the variant. 
 In hopes of getting more data, the lab requests more phenotypic 
data to help reclassify the variant. 
Key Takeaways Integration of higher end genetics concepts (Ex. results name change 
with new testing or reinterpretation). 
Related curriculum Compare preemptive versus reactive testing. 
Explain challenge the uncertainly and evolving knowledge associated 
with interpretation of certain results.  (e.g. VUS, reclassification) 
Defend the opportunity to make decisions regarding the return of 
results as opposed to mandatory return 
e) Applications of whole 
genome sequencing in 
clinical practice   
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
5. Whole genome sequencing technology cannot clinically be used at 
this time to: 
 Diagnose an individual with a predisposition to develop cancer. 
 Diagnose an individual with a predisposition to develop 
complex disease. 
 Identify an individual as a carrier for a condition. 
 Diagnose an individual with a monogenic genetic syndrome. 
Key Takeaways The broadening practice areas where WGS may and may not be useful 
in clinical practice (they should be able to name them). 
Related curriculum Identify when genetics is relevant to your practice. 
Determine which genetic testing technology is most appropriate. 
f) Ordering whole 
genome sequencing 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
6. When consenting a patient to receive genetic testing, which of the 
following results should be discussed as a potential result of 
genome sequencing: 
 Pathogenic mutations 
 Uncertain mutations 
 Secondary mutations 
 Benign mutations 
 Mosaic mutations 
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Key Takeaways How to order WGS, including understanding of insurance coverage, 
result types, etc. 
Related curriculum Identify considerations for selecting a genetic testing laboratory from 
which to order a test. 
Develop procedures for appropriate consenting for WGS. 
Discuss the potential impact of secondary findings in genetic testing. 
Develop a process to estimate the cost of WGS services in the current 
reimbursement landscape 
g) Returning genetic 
testing results 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
7. A pathogenic result found on whole genome sequencing should 
prompt a provider to do all of the following except: 
 Refer the patient to a genetics provider for further follow-up. 
 Identify appropriate resources for the patient. 
 Test family members for the pathogenic finding. 
 Interrogate the result using online resources such as ClinVar 
and OMIM. 
Key Takeaways Key principles of communicating patient results to them including 
post-test counseling interventions. 
Related curriculum Review core concepts in the interpretation WGS results. 
Assess the source of existing test results (e.g., CAP/CLIA, clinical, vs. 
direct-to-consumer, research results) and recommend new testing if 
appropriate. 
Explain the differences between an informative/noninformative results 
and issues surrounding evolving knowledge. 
Identify reliable online resources of genetic information for providers, 
patients, and those whom patients choose to share information. 
Use a culturally sensitive approach to patient counseling regarding test 
results. 
Identify when and how to refer a patient to a genetic specialist. 
h) Clinical integration of 
WGS  
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
8. A patient’s whole genome sequencing results: 
 Can be routinely integrated into current common EHR systems. 
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 Should not be expressly used in patient medical management. 
 Should not be reanalyzed because they already reflect all 
pathogenic variants. 
 Should be stored as a diagnostic report and not as raw data 
in the EHR. 
Key Takeaways Understanding impact of result location. (Ex. cds, annotation options, 
discoverability). 
Related curriculum Describe best practices proper documentation of test results in patient 
heath record. 
Identify challenges associated with the integration of genomic data 
in the EHR.  
Describe the benefits of integrated clinical decision support in the 
EHR.   
Summarize the need for re-classification of genetic test results based 
on updated knowledge.  
i) Ethical, legal, and 
societal implications 
of genetic testing. 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
9. Which statement concerning the ethical, legal, and social 
implications of whole genome sequencing testing true: 
 The Genetic Information Non-Discrimination Act protects 
patients from being discriminated against based on their genetic 
testing results when purchasing disability insurance. 
 All pathogenic findings, including secondary findings should 
always be reported to patients. 
 Genetic testing for adult onset conditions in minors should 
always be conducted if there is a known pathogenic mutation in 
a family member. 
 Genetic testing results are protected under HIPAA. 
Key Takeaways Limitations of GINA and genetic data provided by patients. 
Related curriculum Explain ethical reasons to protect privacy of genetic data.  
Discuss duty to inform. 
Describe the ethical considerations regarding genetic testing under the 
age of 18.   
Recognize the legal protections against discrimination based on 
genetic test results (e.g., the Genetic Information Nondiscrimination 
Act of 2008).  
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KOL Knowledge Question Development 
During the literature review done in preparation for the survey creation, no participatory 
genetics education programs for the general population, such as KOLs in insurance, have been 
created. Therefore, there are no previously published surveys available for this population. 
However, a survey for a similar population of college educated individuals that did not have a 
biology background was available for analysis. Efforts were made in 2007 to create systematically 
validated genetics literacy assessment instruments for undergraduates. This tool was created after 
the statement released in 2002 from the American Society of Human Genetics that included a list 
of benchmarks of genetics concepts for non-science majors, presumably pursuing a bachelor’s 
degree. These benchmarks were then used to narrow down which concepts are necessary for 
genetics literacy. Thirty-one questions based on these concepts were created and validated to 
evaluate genetic literacy in non-biology major undergraduate students[66]. This tool was used as 
an example of how to validate questions about general genetics literacy but is not tailored to 
specific educational programs and focuses more general genetics concepts.  
The knowledge evaluation questions in the ACCOUNT program for KOLs also focused on 
general genetics concepts rather than specific educational takeaways of the program. However,  
knowledge questions developed for the MWGS course for KOLs focused on evaluating participant 
understanding of the information presented to them in the course. The 14 KOL knowledge 
questions developed using the lessons learned from the literature review and previous programs 
are included below in Table 14. The questions were organized by the topic areas selected by the 
research team with one question representing each topic area and paired with the 5-point Likert 
scale knowledge self-assessment included in the survey. For each topic area, the curriculum related 
to the topic area was pulled into the table and used by the research team to create consensus key-
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takeaways. For KOLs, this resulted in the creation of seven multiple choice questions meant to 
assess participant knowledge on the topic areas. The correct answer for each question is bolded. 
Table 14: Knowledge questions for KOLs paired with the topic area the question is evaluating, including 
topic key-takeaway and related curriculum 
a) Precision medicine None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
1. Precision medicine takes into account individual variability in the 
genome to personalize medical management. Common clinical 
applications of precision medicine include all of the following 
EXCEPT:  
 Use of pharmacogenomic (PGx) test results to target 
medication prescribing. 
 Use of polygenic risk scores (PRS) to assess a patient’s 
risk for common diseases. 
 Use of panel genetic testing to assess a patient’s risk for 
common cancers. 
 Use of carrier genetic testing to assess a patient’s risk of 
being a carrier for a rare disease. 
 Use of expansive genetic sequencing to assess a patient’s risk 
of having a genetic condition. 
Key Takeaways Reason for excitement for this precision medicine technology in 
clinical medicine. 
Related curriculum Describe innovations in genetic technologies that have advanced 
scientific knowledge towards precision medicine. 
Explain the value of testing as a screening and prevention strategy to 
improve clinical outcomes at decreased cost. 
Recognize logistical, ethical, legal, and societal issues that impact 
genetic testing and data use in the healthcare setting. 
b) Key genetic 
concepts  
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
2. Mutations are changes in an individual’s DNA and results in a 
different version of the gene. Which of the options below is an 
example of a mutation that, if considered independently, would 
not impact medical management? 
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 A patient with one harmful mutation associated with a 
dominant change in medicine metabolism, such as 
Clopidogrel. 
 A patient with a different number of chromosomes than 
expected, like Down Syndrome. 
 A patient with one harmful mutation for in a common cancer 
risk gene, like BRCA1. 
 A patient with one harmful mutation associated with a 
recessive condition, like Cystic Fibrosis. 
Key Takeaways An individual’s genetic information is variable, and some variations 
can lead to disease risk. 
Related curriculum Define foundational genetics concepts and nomenclature.  
Describe mechanisms of genetic variation that can lead to disease 
and differences in treatment response. 
Differentiate between the clinical diagnosis of disease informed by 
genetics and the identification of genetic predisposition to disease.  
Identify the relevance of genetics in the manifestation and treatment 
of disease. 
Recognize the combined impact of behavioral, social, environmental, 
and genetic factors in the manifestation, prevention, and treatment of 
disease.   
c) Whole genome 
sequencing 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
3. Whole genome sequencing cannot detect: 
 Single nucleotide variants (SNVs) 
 Large structural variants 
 Changes in methylation 
 Copy number variations 
 Mitochondrial DNA variants 
Key Takeaways Understand risks vs benefits and limitations, including technology 
differences between WGS and other genetic testing. 
Related curriculum Differentiate between different genetic testing technologies. 
d) Applications of 
whole genome 
sequencing in 
clinical practice   
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
4. Whole genome sequencing technology cannot clinically be used at 
this time to: 
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 Diagnose an individual with a predisposition to develop 
cancer. 
 Diagnose an individual with a predisposition to develop 
complex disease. 
 Diagnose an individual as a carrier for a condition. 
 Diagnose an individual with a genetic syndrome. 
Key Takeaways Broad understanding of multiple application areas, including 
situations where WGS may not be the best option. 
Related curriculum Describe leading scenarios where whole genome sequencing is 
having a profound impact on healthcare.  




None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
5. Studies have shown that the use of whole genome sequencing: 
 Increases overall cost of healthcare. 
 Decreases testing turnaround time. 
 Has a diagnostic yield higher than other first line genetic 
testing options, such as SNP microarray. 
 Is routinely covered by insurance. 
Key Takeaways There is great need for better coverage of testing and regulation of 
that coverage based on clinical utility data being generated (know 
what is already being reimbursed vs what is not). 
Related curriculum Explain the cost, cost–effectiveness and reimbursement by insurers 
relevant to genomic tests and test interpretation for patients and 
populations. 
Needs for policy (WGS/WES) 
Cost of diagnostic odyssey vs WGS 
Implications for IDFS/vertical vs others 
f) Integration of 
genetic testing 
results into patient 
health record 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
6. A patient’s whole genome sequencing results: 
 Can be routinely integrated into current common EHR 
systems. 
 Should not be expressly used in patient medical management. 
 Should not be reanalyzed because they already reflect all 
pathogenic variants. 
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 Should be stored as a diagnostic report and not as raw 
data. 
Key Takeaways There will be challenges and need for a broad genomics data 
strategy, including what results to store and how to store them in the 
EHR. 
Related curriculum Describe the rationale for having a genomics data strategy. 
Describe best practices proper documentation of test results in 
patient heath record. 
Describe the institutional policies that govern what results it is 
permissible or obligatory to place in the EHR. 
Explain the implications, including benefits and downsides, of 
results being placed in the health record, particularly EHRs. 
Identify challenges associated with the integration of genomic data in 
the EHR (Ex. privacy/security, size/amount/organization of data). 
Describe the benefits of integrated clinical decision support in the 
EHR.  
Summarize the need for reclassification of genetic test results based 
on updated knowledge. 




None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
7. Which statement concerning the ethical, legal, and social 
implications of whole genome sequencing testing true: 
 The Genetic Information Non-Discrimination Act protects 
patients from being discriminated against based on their 
genetic testing results when purchasing disability insurance. 
 All pathogenic findings, including secondary findings, should 
always be reported to patients. 
 Genetic testing for adult onset conditions in minors should 
always be conducted if there is a known pathogenic mutation 
in a family member. 
 Genetic testing results are protected under HIPAA. 
Key Takeaways The coverage limitations of GINA and the complex ELSI 
implications should be thoroughly thought through before 
implementation of this technology. 
Related curriculum Explain ethical reasons to protect privacy of genetic data. 
Examine core concepts in ethics surrounding WGS including the 
discuss duty to inform, legal protections against discrimination based 
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on genetic test results (e.g., the Genetic Information 
Nondiscrimination Act of 2008, state laws), and genetic testing under 
the age of 18.  
Recognize the increased liability that accompanies access to detailed 
genomic patient information and maintaining confidentiality and 
security. 
 
For the two participant groups, there was a fair amount of overlap between the overarching 
curriculum and evaluation questions. For example, both groups will need an introduction to 
precision medicine and WGS, but they will also require different content to accomplish their 
individual learning objectives. The information that the KOLs need to understand the impacts of 
WGS in clinical care will be more focused on economics and outcomes, while the clinicians will 
require a more in-depth introduction and education on the clinical applications. This difference is 
exemplified in the knowledge question content, with more background information being included 
in the questions for KOLs and more clinical terminology for the clinicians. For example, the phrase 
“harmful change” was used for KOLs, and “pathogenic variant” was used for clinicians since 
clinicians will experience the terminology “pathogenic variant” frequently in clinical genetics but 
KOLs may not need to know this distinct phrase, only that the change in the genetic information 
is harmful.  
5.2.3  Evaluation of Participants Attitudes and Perceptions Regarding the Use of Precision 
Medicine and Medical Genetics in Primary Care 
Evaluation of participants’ attitudes and perceptions regarding the use of precision 
medicine and medical genetics has been attempted before, both in the literature and in the previous 
Test2Learn programs. A literature review of current attitudes and perceptions evaluation strategies 
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was conducted and integrated into the attitudes and perceptions questions from the FMR and 
ACCOUNT programs for the creation of the questions for clinicians and KOLs who will 
participate in the MWGS program. 
While whole genome sequencing (WGS) has applications in all forms of healthcare, it has 
not yet been widely utilized in primary care, though physicians are reporting its eventual use as 
inevitable [1, 67]. The major concerns shown to influence the decision to utilize genetic testing are 
clinical utility of results, data security and privacy of results, impact of results on health insurance 
eligibility, impact of results on life insurance eligibility, impact of results on employment 
discrimination, and fear of learning their results [6, 9, 10, 13, 25, 62, 68]. Evaluation of these 
factors for clinicians has been conducted by PMRPs, MEPs, GMEPs, and CMEPs, so there is more 
data, both longitudinally and overall, for these factors for providers. Evaluation of these factors 
for patients and the general population has been more limited, being conducted in some PMRPs 
and community education projects. Due to this limited sampling, participants included in these 
projects may not be representative of the general population.   
In evaluating the perceived clinical utility of genetic sequencing data, which can influence 
the decision to undergo testing, clinicians and the public are both identifying benefits of WGS that 
are not typically considered, such as family planning and testing, intrinsic value of information, 
and the ability to prepare for the future [24]. For example, patient participants of the BabySeq 
project seemed to have a more favorable benefit/risk ratio of WGS than the clinician participants 
surveyed for this project, which may be indicative of the general population or may be limited to 
the patient population surveyed by this project  [24]. Healthy individuals included in the PeopleSeq 
Consortium were enthusiastic about their experience of undergoing pre-dispositional sequencing 
and not distressed by their results, reporting value in their health related results and agreeing that 
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genetic testing results should be available in the medical record for clinical use [13]. Participants 
included in focus groups conducted by the Geisinger MyCode Community Health Initiative also 
agree that genomic results should be returned as part of the precision medicine project despite 
possible anxiety or lack of clinical actionability, indicating that these factors would not deter them 
from pursuing genetic sequencing [17]. 
As part of the PMRPs that were initially focused purely on genetics research and not return 
of patient results, participants were heavily surveyed on their attitudes and perceptions around 
genetic results. Projects utilized the hospital depression and anxiety scale to survey patient 
participants mental health concerning the decision to be part of the research project and did not 
find that participating increased participant depression or anxiety for the majority of participants 
[16, 69].  
As part of the initial MEPs, GMEPs, and CMEPs programs that initially utilized 
participatory educational interventions, participant comfort was heavily surveyed. Participant 
decision regret to utilize or not utilize their own genetic information as part of the educational 
program was evaluated using the validated decision-regret scale [70]. Participant anxiety about the 
decision to utilize or not utilize their own genetic information as part of the educational program 
was evaluated using the validated shortened version of the intolerance of uncertainty scale [71]. 
Participant depression related to their decision to utilize or not utilize their own genetic information 
as part of the educational program was evaluated using the validated two-item patient health 
questionnaire [72].  
As the survey for the MWGS program was created, major changes to the attitudes and 
perceptions questions focused on more targeted analysis and potential scholarship from findings. 
In the analysis of the ACCOUNT program iterations, it was found that many of the questions may 
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not have been useful. This finding combined with the low-response rate and indication of survey 
fatigue encouraged the research team to be more targeted in the questions asked in this final section 
of the survey. Due to the consistent findings presented in the literature and findings of the previous 
program iterations, questions regarding participant depression and decision-regret were not 
included in this program. Participant perceptions and attitudes evaluation attempted to have a 
similar analysis compared to previous program surveys but was more targeted to WGS and its 
clinical uses and consolidated to 20 questions. The full survey for both participant populations can 
be found and further reviewed in Appendix C. 
5.3 Discussion 
Overall, analysis of the ACCOUNT and FMR programs was limited due to the low 
response rate for the post-course survey and overall small population, but there were still many 
lessons to be learned to help guide the creation of the MWGS program surveys. Analysis of the 
previous program survey data showed both areas of success and opportunities for improvement 
for the survey scaffolding adapted for the MWGS program survey.  
A key area for improvement was to cut down on the overall number of questions asked to 
increase participant responses and decrease survey fatigue. This goal was accomplished with an 
overall decrease in clinician survey length by 33% and a decrease in KOLs survey length by 24%. 
Additional interventions will be made during the launch of the program to try to increase survey 
completion, such as breaking up the survey sections instead of administering all questions at once. 
A major limitation of the creation of this survey is that the timeline for this project did not 
allow for the survey to be tested on any population before completion of this essay. While the 
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survey was able to utilize lessons learned from previous programs, final changes before 
widespread dissemination are not documented here as they have not yet occurred. After much 
discussion, the research team believes that the initial administration of the course during the 
Precision Medicine World Conference (PMWC) that is planned to be hosted in person in 
Pittsburgh in September 2021 will be the true pilot of the MWGS program. At that time, 140 
participants are expected to be enrolled in the program. The technical aspects will be piloted before 
this launch, but the entirety of the program will be piloted with this event. This cohort will be the 
pilot, especially since a participant group of 140 is still fairly small, and anyone that the research 
team would include in pilot testing of the program will most likely also be present and recruited at 
the PMWC. This leaves the opportunity for future changes before the final launch of the course 
and the pre- and post-course surveys after the piloting phase is complete. Final launch of the 
program will be when the program is made widely available on the web-based platform for 
clinicians and KOLs in different locations to receive this novel education program. 
Final surveys that are launched with the program are expected to be much the same and 
allow for continued cross sectioned studies of the program and its efficacy over time. Changes 
made after pilot survey analysis will allow for fine tuning of the survey. Hopefully, this survey 
will also be able to be the base from which further, longitudinal research can be conducted with 
updated versions to be administered at more long-term timepoints. 
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Appendix A Data Analysis 
Appendix A.1 FMR Educational Program Institutional Review Board Approval 
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Appendix B Survey Materials 
Appendix B.1 ACCOUNT Educational Program Surveys 
Appendix B.1.1 Healthcare Provider Pre-Course Survey 
Demographics (Providers/Staff): 
 
What is your current age? 
 18 to 24 years 
 25 to 34 years 
 35 to 44 years 
 45 to 54 years 
 55 to 64 years 
 Age 65 or older 
 
Please select your gender? 
 (0) Male 
 (1) Female 
 (2) Transgender Female 
 (3) Transgender Male 
 (4) Gender Variant/Non-conforming 
 (5) Not listed 
 (6) Prefer Not to Answer 
 
 
What best describes your current position (select one only): 
 (0) Physician Resident 
 (1) Pharmacy Resident 
 (2) Graduate Program (master’s or Ph.D.) 
 (3) Fellowship 
 (4) M.D./D.O. 
 (5) NP/PA 
 (6) PharmD/RPh 
 (7) RN/MA 
 (8) Staff 
 (9) other: ________________ 
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In what year did you complete your advanced degree program (MD, PharmD)? 








What is your current or anticipated future career direction in primary care? 
 (0) Clinical – inpatient 
 (1) Clinical – community 
 (2) Long term care 
 (3) Consultant 
 (4) Academia 
 (5) Industry 
 (6) not sure 
 (7) n/a 
 
Please select what best describes your previous education regarding genetics 
 (1) None 
 (2) Biology course 
 (3) Specific course on genetics 























Knowledge of Genetics and Pharmacogenomics (Providers/Staff): 
 
Rate your level of understanding on a scale of 1 to 5 on the following subjects  
(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above average 
understanding; 5=expert understanding),  
 
please rate your knowledge of the following: 
 
 
Pharmacogenomics   
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Genetics of complex disease None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Carrier Status Testing  None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Basic genetic principles  None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Precision medicine None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
The risks of pharmacogenomic 
testing 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
The benefits of pharmacogenomic 
testing 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Gene-environment interactions None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
How to interpret 
pharmacogenomic test results 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
How pharmacogenomic test results 
are used in clinical practice 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
 96 
The impact of African American 
ancestry on health care decision 
making 
None Minimal Moderate Above 
Average 
Expert 




about cardiovascular medications 
in patients with African American 
ancestry 
 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
History of African Americans in 
research in America  
None Minimal Moderate Above 
Average 
Expert 






Humans are over 99% identical at the DNA level. 
 True (0) 
 False (1) 
 
Most cells in the body contain 47 chromosomes. 
 True (0) 
 False (1) 
 
Some genetic conditions, such as sickle cell anemia, are caused by a mutation in a single gene. 
 True (0) 
 False (1) 
 
A person’s genotype is not expected to change over a person’s lifetime. 
 True (0) 
 False (1) 
 
There are ethnic contributions to variations in drug metabolism of cardiac medications. 
 True (0) 
 False (1) 
 
Diseases, such as diabetes and heart disease, are caused by a change in a single gene. 
 True (0) 




Prevalence of many Mendelian diseases differs by ethnic groups. 
 True (0) 
 False (1) 
 
Differences in a person’s genome can explain >30% of the overall variability on a drug’s 
pharmacokinetics and/or pharmacodynamics. 
 True (0) 
 False (1) 
 
Drugs have pharmacogenomic information in their FDA approved product labeling. 
 True (0) 
 False (1) 
 
The product labeling for warfarin includes specific recommendations for dosing in patients with 
certain genetic variants. 
 True (0) 
 False (1) 
 
The genetic variation in clopidogrel (Plavix) metabolism is due to differences of the CYP451 
enzyme. 
 True (0) 
 False (1) 
 
Personal genomic testing is available without a prescription. 
 True (0) 
 False (1) 
 
Guidelines recommend tailoring of blood pressure medications based on pharmacogenomics.  
 True (0) 




Attitudes/Perceptions Regarding the Use of Pharmacogenomics and Precision Medicine 
(Providers/Staff): 
Do you feel you would benefit from additional education/training in genomic medicine?  
 Yes (0) 
 No (1) 
 
Please indicate your preferred mode of learning about genomic medicine:  
 (0) Professional meetings 
 (2) Laboratory representative 
 (3) Peer-reviewed publications/journals 
 (4) Online CME learning 
 (5) In-person CME learning (e.g., grand rounds or other in-house seminars) 
 (6) Just-in-time (point-of-care, reminder notice through electronic medical record) 
 (7) Other (please specify) ____________________ 
 
 
Do you plan on personally undergoing genetic testing as part of this course?  
 Yes (0) 
 No (1)  
Would you have made the same decision if you had been told the result would be entered into  
your medical record? 
 Yes (0) 
 No (1) 
 
Did concerns regarding any of the following affect your decision to undergo testing.  
 Data security/privacy (0) 
 Impact on health insurance eligibility (1) 
 Impact on life insurance eligibility (2) 
 Employment discrimination (3) 

















In general, how useful do you feel the following testing will be to you in the clinical setting? 
 
 









 1  2  3  4  
 









 1  2  3  4  
 









 1  2  3  4  
 











 1  2  3  4  
 
 
Most primary care physicians have enough knowledge to help individuals interpret the results of 
the following types of tests: 
(1=strongly disagree; 2= disagree; 3=neutral; 4=agree; 5=strongly agree)  
 
 
Pharmacogenomic Testing Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
Prenatal Carrier Testing Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 





Disagree Neutral Agree Strongly 
Agree 
 






Most primary care physicians have enough knowledge to ensure patients understand the risks 
and benefits surrounding the following types of tests: 
(1=strongly disagree; 2= disagree; 3=neutral; 4=agree; 5=strongly agree)  
 
 
Pharmacogenomic Testing  Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
  1  2  3  4  5 
 
Prenatal Carrier Testing Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
 
 1  2  3  4  5  
 




Disagree Neutral Agree Strongly 
Agree 
 
 1  2  3  4  5  
 





Disagree Neutral Agree Strongly 
Agree 




All primary care providers should be 





Disagree Neutral Agree Strongly 
Agree 




Part of a primary care physician’s 
role should include counseling 





Disagree Neutral Agree Strongly 
Agree 




In the future, pharmacogenomic 
testing will routinely be used to 





Disagree Neutral Agree Strongly 
Agree 




How likely is it that knowing genetic 
information about yourself would 














Personalized genetic testing 
companies provide an accurate 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
  
Most people can accurately interpret 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable explaining 
the process of pharmacogenomic 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable discussing 





Disagree Neutral Agree Strongly 
Agree 




If you were to undergo personalized genomic testing, would you share your results with your 
personal physician? 
 Yes (0) 
 No (1) 
 
If you were to undergo personalized genomic testing, would you ask a health care provider for 
help in interpreting the results? 
 Yes (0) 
 No (1) 
 
Would you at this time recommend personalized genomic testing for a patient? 
 Yes (0) 
 No (1) 
 
Are you aware of direct-to-consumer genetics testing (e.g 23andMe, etc.)?  
 Yes (0) 
 No (1) 
 
Have you personally ever had genetic testing performed?  
 Yes (0) 
 No (1) 
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Has anyone close to you had genetic testing performed (e.g., parent, child, sibling, friend)?  
 Yes (0) 
 No (1) 
 
In your practice, have you had a patient bring genetic test results to you?    
 Yes (0) 
 No (1) 
 
In past year, how often have you ordered or used the following genetic testing services to 
manage your patients? 
 
a. Pharmacogenomics? 
 (0)  Never or not familiar with the testing 
 (1) Rarely (1-5 per year) 
 (2) Occasionally (6-10 per year) 
 (3) Frequently (11+ per year) 
 
b. Diagnostic genetic testing (e.g. Huntington’s Chorea, hypertrophic cardiomyopathy)? 
 (0)  Never or not familiar with the testing 
 (1) Rarely (1-5 per year) 
 (2) Occasionally (6-10 per year) 
 (3) Frequently (11+ per year) 
 
 
c. Carrier Testing (e.g. CF, Tay-Sachs) 
 (0)  Never or not familiar with the testing 
 (1) Rarely (1-5 per year) 
 (2) Occasionally (6-10 per year) 





d. Cancer Risk Testing (e.g. BRCA, Lynch) 
 (0)  Never or not familiar with the testing 
 (1) Rarely (1-5 per year) 
 (2) Occasionally (6-10 per year) 
 (3) Frequently (11+ per year) 
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 In the past year, which testing technologies have you ordered or used to manage your patients 
(check all that apply)?  
 (0) Not applicable (have not used) 
 (1) Karyotyping 
 (2) Single gene tests 
 (3) Multiple gene panels 
 (4) Microarray-based testing 
 (5) Targeted sequencing 
 (6) Whole genome or exome sequencing 
 (7) Not sure of the type  
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Attitudes/Perceptions Regarding the ALL of Us Precision Medicine Program 
(Providers/Staff): 
Have you heard of the All of Us Research Program? 
 Yes (0) 
 No (1) 
 
Have you heard a presentation about the All of Us Research Program?  
 Yes (0) 
 No (1) 
 
Have you enrolled in the All of Us Research Program? 
 Yes (0) 
 No (1) 
 
Do you know anyone who has enrolled in the All of Us Research Program? 
 Yes (0) 




How likely are you to tell a 









 1  2  3  4  5 
  
How likely are you to 
encourage a patient to enroll 













How confident do you feel in 
discussing the all of the All of 








 1  2  3  4  5 
  
 
Do you feel you have enough education about the All of Us Research Program to 
promote enrollment? 
 Yes (0) 
 No (1) 
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Appendix B.1.2 Community Member Pre-Course Survey 
Demographics (Advisory Board): 
 What is your current age? 
 18 to 24 years 
 25 to 34 years 
 35 to 44 years 
 45 to 54 years 
 55 to 64 years 
 Age 65 or older 
 
Please select your gender? 
 (0) Male 
 (1) Female 
 (2) Transgender Female 
 (3) Transgender Male 
 (4) Gender Variant/Non-conforming 
 (5) Not listed 
 (6) Prefer Not to Answer 
 
What best describes your current position (select one only): 
 (0) Community Board Member 
 (1) Other ________________ 
 
What is the highest education level you have completed? 
 (0) less than a high school diploma 
 (1) high school degree or equivalent (GED) 
 (2) some college, no degree 
 (3) Associate degree (AA, AS) 
 (4) Bachelor’s degree (BA, BS) 
 (5) Master’s degree (MA, MS, Med) 
 (6) Professional degree (MD, DDS, DVM) 
 (7) Doctorate (PhD, EdD)  
 
What is your ethnicity? (select all that apply) 
 (0) Black or African American 
 (1) White 
 (2) Hispanic or Latino 
 (3) Native American or American Indian 
 (4) Asian/Pacific Islander 
 (5) Middle Eastern/North African 
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Are you currently? 
 (0) Employed full time (40 or more hours per week) 
 (1) Employed part time (up to 39 hours per week) 
 (2) Unemployed and currently looking for work 
 (3) Unemployed and not currently looking for work 
 (4) Student 
 (5) Retired 
 (6) Homemaker 
 (7) Self-employed 
 (8) unable to work 
 
Do you currently make in one year? 
 (0) Less than $20,000 
 (1) $20,000 to $34,999 
 (2) $35,000 to $49,999 
 (3) $50,000 to $74,999 
 (4) over $100,000 





Knowledge of Genetics and Pharmacogenomics (Advisory Board): 
 
Rate your knowledge on a scale of 1 to 5 on the following subjects  
(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above average 
understanding; 5=expert understanding),  
 
please rate your knowledge of the following: 
Understanding of genetic 
contributions to your health 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Understanding of the concept of 
Pharmacogenomics 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Understanding of the concept of 
Precision Medicine 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
The impact of African American 
ancestry on health care decision 
making 
None Minimal Moderate Above 
Average 
Expert 





Humans are over 99% identical at the DNA level. 
 True (0) 
 False (1) 
 
Most cells in the body contain 47 chromosomes. 
 True (0) 
 False (1) 
 
Pharmacogenomic testing is currently available for most medications. 
 True (0) 
 False (1) 
 
Personal genomic testing (like 23andMe) is available to consumers and can be done without a 
prescription. 
 True (0) 
 False (1) 
 
Most common diseases, such as diabetes and heart disease, are caused by a single mutation on 
one gene. 
 True (0) 
 False (1) 
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A person’s genotype (genetic code) is not expected to change over a person’s lifetime. 
 True (0) 
 False (1) 
 
There are ethnic contributions to variations in drug metabolism that impact multiple cardiac 
medications. 
 True (0) 







Attitudes/Perceptions Regarding the Use of Pharmacogenomics and Precision Medicine 
(Advisory Board): 
Do you feel you would benefit from education in genomic medicine?  
 Yes (0) 
 No (1) 
 
Do you plan on personally undergoing genetic testing as part of this course?  
 Yes (0) 
 No (1) 
 
Would you have made the same decision if you had been told the result would be entered into  
your medical record? 
 Yes (0) 
 No (1) 
  
Would you have made the same decision if this course also offered genetic testing to determine  
your predisposition to a variety of common diseases (e.g. diabetes, cardiovascular disease)? 
 Yes (0) 
 No (1) 
 
In general, how important are the following tests to understanding and managing your personal health? 
 









 1  2  3  4  
 









 1  2  3  4  
 









 1  2  3  4  
 
















Most primary care physicians have enough knowledge to help individuals interpret the results of 
the following types of tests: 
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(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above average 
understanding; 5=expert understanding)  
 
Pharmacogenomic Testing None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Prenatal Carrier Testing None Minimal Moderate Above 
Average 
Expert 




Cancer Genetic Carrier Testing None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Direct to Consumer Testing 
 
None Minimal Moderate Above 
Average 
Expert 


























Most primary care physicians have enough knowledge to ensure patients understand the risks 
and benefits surrounding the following types of tests: 
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(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above average 
understanding; 5=expert understanding)  
 
Pharmacogenomic Testing None Minimal Moderate Above 
Average 
Expert 




Prenatal Carrier Testing None Minimal Moderate Above 
Average 
Expert 




Cancer Genetic Carrier Testing None Minimal Moderate Above 
Average 
Expert 




Direct to Consumer Testing 
 
None Minimal Moderate Above 
Average 
Expert 






All primary care providers should be 





Disagree Neutral Agree Strongly 
Agree 




Part of a primary care physician’s 
role should include counseling 





Disagree Neutral Agree Strongly 
Agree 




In the future, pharmacogenomic 
testing will routinely be used to 





Disagree Neutral Agree Strongly 
Agree 




How likely is it that knowing genetic 








lead to changes in your own 
behavior? 
 




Personalized genomic testing 
companies provide an accurate 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
  
Most people can accurately interpret 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable if my PCP 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable having my 
PCP explain the process of 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable discussing 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable discussing 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
 
If you were to undergo personalized genomic testing, would you share your results with your 
personal physician? 
 Yes (0) 
 No (1) 
 
If you were to undergo personalized genomic testing, would you ask a health care provider for 
help in interpreting the results? 
 Yes (0) 
 No (1) 
 
Would you at this time recommend personalized genomic testing for a friend or family member? 
 Yes (0) 
 No (1) 
 
Prior to this course were you previously aware of direct-to-consumer genetics testing (e.g 
23andMe, etc)?  
 Yes (0) 
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 No (1) 
 
Have you personally ever had genetic testing performed?  
 Yes (0) 
 No (1) 
 
 
Has anyone close to you had genetic testing performed (e.g., parent, child, sibling, friend)?  
 Yes (0) 
 No (1) 
 
If you had personalized genomic testing done, did you share your results with your PCP?    
 Yes (0) 
 No (1) 
 
As far as you are aware, have you ever had the following types of testing offered to you? (mark 
all that apply) 
 Pharmacogenomics 
 Diagnostic genetic testing (e.g. Huntington’s Chorea, hypertrophic cardiomyopathy) 
 Carrier Testing (e.g. CF, Tay-Sachs) 





Attitudes/Perceptions Regarding the ALL of Us Precision Medicine Program (Advisory 
Board): 
Have you heard of the All of Us Research Program? 
 Yes (0) 
 No (1) 
 
Have you heard a presentation about the All of Us Research Program?  
 Yes (0) 
 No (1) 
 
Have you enrolled in the All of Us Research Program? 
 Yes (0) 
 No (1) 
 
Do you know anyone who has enrolled in the All of Us Research Program? 
 Yes (0) 
 No (1) 
 
 
How likely are you to tell a 
friend or family member 









 1  2  3  4  5 
  
How likely are you to 
encourage a friend or family 
member to enroll in the All of 












How confident do you feel in 
discussing the all of the All of 








 1  2  3  4  5 
  
 
Do you feel you have enough education about the All of Us Research Program to promote 
enrollment? 
 Yes (0) 
 No (1) 
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Appendix B.1.3 Healthcare Provider Post-Course Survey 
Course Expectations (Providers/Staff): 
What elements of the course will you expect to be most difficult to master in your routine 
practice?  
What suggestions do you have for overcoming these difficulties?  
Do you have any other comments, questions, or feedback? 
 
The following have been valuable to you in your learning experience:  
 




   Strongly 
Agree 
 1  2  3  4  5 
 
The live course Strongly 
Disagree 
   Strongly 
Agree 
 1  2  3  4  5 
 





   Strongly 
Agree 
 1  2  3  4  5 
 
Clear learning objectives Strongly 
Disagree 
   Strongly 
Agree 
 1  2  3  4  5 
 
Detailed course outline Strongly 
Disagree 
   Strongly 
Agree 










Knowledge of Genetics and Pharmacogenomics (Providers/Staff): 
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Rate your level of understanding on a scale of 1 to 5 on the following subjects  
(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above average 
understanding; 5=expert understanding),  
 
please rate your knowledge of the following: 
 
Pharmacogenomics   
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Genetics of complex disease None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Carrier Status Testing  None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Basic genetic principles  None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Precision medicine None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
The risks of pharmacogenomic 
testing 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
The benefits of pharmacogenomic 
testing 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Gene-environment interactions None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
How to interpret 
pharmacogenomic test results 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
How pharmacogenomic test results 
are used in clinical practice 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
The impact of African American 
ancestry on health care decision 
making 








about cardiovascular medications 
in patients with African American 
ancestry 
 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
History of African Americans in 
research in America  
None Minimal Moderate Above 
Average 
Expert 






Humans are over 99% identical at the DNA level. 
 True (0) 
 False (1) 
 
Most cells in the body contain 47 chromosomes. 
 True (0) 
 False (1) 
 
Some genetic conditions, such as sickle cell anemia, are caused by a mutation in a single gene. 
 True (0) 
 False (1) 
 
A person’s genotype is not expected to change over a person’s lifetime. 
 True (0) 
 False (1) 
 
There are ethnic contributions to variations in drug metabolism that impact multiple cardiac 
medications. 
 True (0) 





Most common diseases, such as diabetes and heart disease, are caused by a change in a single 
gene. 
 True (0) 
 False (1) 
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Prevalence of many Mendelian diseases differs by ethnic groups. 
 True (0) 
 False (1) 
 
Subtle differences in a person’s genome can have a major impact (eg. explain >30% of the 
overall variability) on a drug’s pharmacokinetics and/or pharmacodynamics. 
 True (0) 
 False (1) 
 
Drugs have pharmacogenomic information in their FDA approved labeling. 
 True (0) 
 False (1) 
 
The product labeling (package insert) for warfarin includes specific recommendations for dosing 
in patients that have specific genetic variants. 
 True (0) 
 False (1) 
 
The genetic variation in clopidogrel (Plavix) metabolism is due to differences of the CYP451 
enzyme. 
 True (0) 
 False (1) 
 
Personal genomic testing is available to consumers and can be done without a prescription. 
 True (0) 
 False (1) 
 
Guidelines recommend tailoring of blood pressure medications based on pharmacogenomics.  
 True (0) 








Attitudes/Perceptions Regarding the Use of Pharmacogenomics and Precision Medicine 
(Providers/Staff): 
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Did this course inspire you to seek additional education/training in genomic or precision 
medicine? 
 Yes (0) 
 No (1) 
 
Please indicate your preferred mode of learning about genomic medicine:  
 (0) Professional meetings 
 (2) Laboratory representative 
 (3) Peer-reviewed publications/journals 
 (4) Online CME learning 
 (5) In-person CME learning (e.g., grand rounds or other in-house seminars) 
 (6) Just-in-time (point-of-care, reminder notice through electronic medical record) 
 (7) Other (please specify) ____________________ 
 
   
Did you personally undergo genetic testing as part of this course?  
 Yes (0) 
 No (1)  
Would you have made the same decision if you had been told the result would be entered into  
your medical record? 
 Yes (0) 
 No (1) 
 
Did concerns regarding any of the following affect your decision to undergo testing.  
 Data security/privacy (0) 
 Impact on health insurance eligibility (1) 
 Impact on life insurance eligibility (2) 
 Employment discrimination (3) 













In general, how useful do you feel the following testing will be to you in the clinical setting? 
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 1  2  3  4  
 









 1  2  3  4  
 









 1  2  3  4  
 











 1  2  3  4  
 
 
Most primary care physicians have enough knowledge to help individuals interpret the results of 
the following types of tests: 
(1=strongly disagree; 2= disagree; 3=neutral; 4=agree; 5=strongly agree)  
 
Pharmacogenomic Testing Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
Prenatal Carrier Testing Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 





Disagree Neutral Agree Strongly 
Agree 
 







Most primary care physicians have enough knowledge to ensure patients understand the risks 
and benefits surrounding the following types of tests: 
(1=strongly disagree; 2= disagree; 3=neutral; 4=agree; 5=strongly agree)  
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Pharmacogenomic Testing  Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
  1  2  3  4  5 
 
Prenatal Carrier Testing Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
 
 1  2  3  4  5  
 




Disagree Neutral Agree Strongly 
Agree 
 
 1  2  3  4  5  
 





Disagree Neutral Agree Strongly 
Agree 




All primary care providers should be 





Disagree Neutral Agree Strongly 
Agree 




Part of a primary care physician’s 
role should include counseling 





Disagree Neutral Agree Strongly 
Agree 




In the future, pharmacogenomic 
testing will routinely be used to 





Disagree Neutral Agree Strongly 
Agree 




How likely is it that knowing genetic 
information about yourself would 













Personalized genetic testing 
companies provide an accurate 




Disagree Neutral Agree Strongly 
Agree 




Most people can accurately interpret 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable explaining 
the process of pharmacogenomic 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable discussing 





Disagree Neutral Agree Strongly 
Agree 




If you were to undergo personalized genomic testing, would you share your results with your 
personal physician? 
 Yes (0) 
 No (1) 
 
If you were to undergo personalized genomic testing, would you ask a health care provider for 
help in interpreting the results? 
 Yes (0) 
 No (1) 
 
Would you at this time recommend personalized genomic testing for a patient? 
 Yes (0) 
 No (1) 
 
Are you aware of direct-to-consumer genetics testing (e.g 23andMe, etc.)?  
 Yes (0) 
 No (1) 
 
Have you personally ever had genetic testing performed?  
 Yes (0) 
 No (1) 
 
Has anyone close to you had genetic testing performed (e.g., parent, child, sibling, friend)?  
 Yes (0) 
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 No (1) 
 
In your practice, have you had a patient bring genetic test results to you?    
 Yes (0) 
 No (1) 
 
In the past year, how often have you ordered or used the following genetic testing services to 
manage your patients? 
a. Pharmacogenomics? 
 (0)  Never or not familiar with the testing 
 (1) Rarely (1-5 per year) 
 (2) Occasionally (6-10 per year) 
 (3) Frequently (11+ per year) 
 
b. Diagnostic genetic testing (e.g. Huntington’s Chorea, hypertrophic cardiomyopathy)? 
 (0)  Never or not familiar with the testing 
 (1) Rarely (1-5 per year) 
 (2) Occasionally (6-10 per year) 
 (3) Frequently (11+ per year) 
 
c. Carrier Testing (e.g. CF, Tay-Sachs) 
 (0)  Never or not familiar with the testing 
 (1) Rarely (1-5 per year) 
 (2) Occasionally (6-10 per year) 
 (3) Frequently (11+ per year) 
 
d. Cancer Risk Testing (e.g. BRCA, Lynch) 
 (0)  Never or not familiar with the testing 
 (1) Rarely (1-5 per year) 
 (2) Occasionally (6-10 per year) 





In the past year, which testing technologies have you ordered or used to manage your patients 
(check all that apply)?  
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 (0) Not applicable (have not used) 
 (1) Karyotyping 
 (2) Single gene tests 
 (3) Multiple gene panels 
 (4) Microarray-based testing 
 (5) Targeted sequencing 
 (6) Whole genome or exome sequencing 
 (7) Not sure of the type  
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Attitudes/Perceptions Regarding the ALL of Us Precision Medicine Program 
(Providers/Staff): 
 
Have you heard of the All of Us Research Program? 
 Yes (0) 
 No (1) 
 
Have you heard a presentation about the All of Us Research Program?  
 Yes (0) 
 No (1) 
 
Have you enrolled in the All of Us Research Program? 
 Yes (0) 
 No (1) 
 
Do you know anyone who has enrolled in the All of Us Research Program? 
 Yes (0) 
 No (1) 
 
How likely are you to tell a 









 1  2  3  4  5 
  
How likely are you to 
encourage a patient to enroll 













How confident do you feel in 
discussing the all of the All of 








 1  2  3  4  5 
  
 
Do you feel you have enough education about the All of Us Research Program to promote 
enrollment? 
 Yes (0) 




Appendix B.1.4 Community Member Post-Course Survey 
Knowledge of Genetics and Pharmacogenomics (Advisory Board): 
 
Rate your knowledge on a scale of 1 to 5 on the following subjects  
(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above average 
understanding; 5=expert understanding),  
please rate your knowledge of the following: 
Understanding of genetic 
contributions to your health 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Understanding of the concept of 
Pharmacogenomics 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Understanding of the concept of 
Precision Medicine 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
The impact of African American 
ancestry on health care decision 
making 
None Minimal Moderate Above 
Average 
Expert 





Humans are over 99% identical at the DNA level. 
 True (0) 
 False (1) 
 
Most cells in the body contain 47 chromosomes. 
 True (0) 
 False (1) 
 
Pharmacogenomic testing is currently available for most medications. 
 True (0) 
 False (1) 
 
Personal genomic testing (like 23andMe) is available to consumers and can be done without a 
prescription. 
 True (0) 
 False (1) 
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Most common diseases, such as diabetes and heart disease, are caused by a single mutation on 
one gene. 
 True (0) 
 False (1) 
 
A person’s genotype (genetic code) is not expected to change over a person’s lifetime. 
 True (0) 
 False (1) 
 
There are ethnic contributions to variations in drug metabolism that impact multiple cardiac 
medications. 
 True (0) 






Attitudes/Perceptions Regarding the Use of Pharmacogenomics and Precision Medicine 
(Advisory Board): 
Do you personally undergo genetic testing as part of this course?  
 Yes (0) 
 No (1) 
 
Would you have made the same decision if you had been told the result would be entered into  
your medical record? 
 Yes (0) 
 No (1)  
Would you have made the same decision if this course also offered genetic testing to determine  
your predisposition to a variety of common diseases (e.g. diabetes, cardiovascular disease)? 
 Yes (0) 
 No (1) 
 
In general, how important are the following tests to understanding and managing your personal health? 
 









 1  2  3  4  
 









 1  2  3  4  
 









 1  2  3  4  
 























Most primary care physicians have enough knowledge to help individuals interpret the results of 
the following types of tests: 
 
(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above average 
understanding; 5=expert understanding)  
 
Pharmacogenomic Testing None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Prenatal Carrier Testing None Minimal Moderate Above 
Average 
Expert 




Cancer Genetic Carrier Testing None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Direct to Consumer Testing 
 
None Minimal Moderate Above 
Average 
Expert 

























Most primary care physicians have enough knowledge to ensure patients understand the risks 
and benefits surrounding the following types of tests: 
 
(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above average 
understanding; 5=expert understanding)    
 
Pharmacogenomic Testing None Minimal Moderate Above 
Average 
Expert 




Prenatal Carrier Testing None Minimal Moderate Above 
Average 
Expert 




Cancer Genetic Carrier Testing None Minimal Moderate Above 
Average 
Expert 




Direct to Consumer Testing 
 
None Minimal Moderate Above 
Average 
Expert 






All primary care providers should be 





Disagree Neutral Agree Strongly 
Agree 




Part of a primary care physician’s 
role should include counseling 





Disagree Neutral Agree Strongly 
Agree 




In the future, pharmacogenomic 
testing will routinely be used to 





Disagree Neutral Agree Strongly 
Agree 





How likely is it that knowing genetic 
information about yourself would 













Personalized genomic testing 
companies provide an accurate 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
  
Most people can accurately interpret 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable if my PCP 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable having my 
PCP explain the process of 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable discussing 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable discussing 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
 
If you were to undergo personalized genomic testing, would you share your results with your 
personal physician? 
 Yes (0) 
 No (1) 
 
If you were to undergo personalized genomic testing, would you ask a health care provider for 
help in interpreting the results? 
 Yes (0) 
 No (1) 
 
Would you at this time recommend personalized genomic testing for a friend or family member? 
 Yes (0) 
 No (1) 
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Prior to this course were you previously aware of direct-to-consumer genetics testing (e.g 
23andMe, etc)?  
 Yes (0) 
 No (1) 
 
Have you personally ever had genetic testing performed before this course?  
 Yes (0) 
 No (1) 
 
Has anyone close to you had genetic testing performed (e.g., parent, child, sibling, friend)?  
 Yes (0) 
 No (1) 
 
If you had personalized genomic testing done, did you share your results with your PCP?    
 Yes (0) 
 No (1) 
 
As far as you are aware, have you ever had the following types of testing offered to you? (mark 
all that apply) 
 Pharmacogenomics 
 Diagnostic genetic testing (e.g. Huntington’s Chorea, hypertrophic cardiomyopathy) 
 Carrier Testing (e.g. CF, Tay-Sachs) 




Attitudes/Perceptions Regarding the ALL of Us Precision Medicine Program (Advisory 
Board): 
 
Have you heard of the All of Us Research Program? 
 Yes (0) 
 No (1) 
 
Have you heard a presentation about the All of Us Research Program?  
 Yes (0) 
 No (1) 
 
Have you enrolled in the All of Us Research Program? 
 Yes (0) 
 No (1) 
 
Do you know anyone who has enrolled in the All of Us Research Program? 
 Yes (0) 
 No (1) 
 
How likely are you to tell a 
friend or family member 









 1  2  3  4  5 
  
How likely are you to 
encourage a friend or family 
member to enroll in the All of 












How confident do you feel in 
discussing the all of the All of 








 1  2  3  4  5 
  
 
Do you feel you have enough education about the All of Us Research Program to promote 
enrollment? 
 Yes (0) 
 No (1) 
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Appendix B.2 FMR Educational Program Surveys 
Appendix B.2.1 Pre-Course Survey 
Demographics: 
What is your current age? 
 18 to 24 years 
 25 to 34 years 
 35 to 44 years 
 45 to 54 years 
 55 to 54 years 
 Age 65 or older 
 
Please select your gender? 
 (0) Male 
 (1) Female 
 (2) Transgender Female 
 (3) Transgender Male 
 (4) Gender Variant/Non-conforming 
 (5) Not listed 
 (6) Prefer Not to Answer 
 
What best describes your current position (select one only): 
 (0) Physician Resident 
 (1) Pharmacy Resident 
 (2) Graduate Program (Masters or Ph.D.) 
 (3) Fellowship 
 (4) M.D./D.O. 
 (5) NP/PA 
 (6) RN/MA 
 (7) Staff 






What is your current or anticipated future career direction in primary care? 
 (0) Clinical – inpatient 
 (1) Clinical – community 
 (2) Long term care 
 (3) Consultant 
 (4) Academia 
 (5) Industry 
 (6) not sure 
 (7) n/a 
 
In what year did you complete you advanced degree program (MD, PharmD)? 









Please select what best describes your previous education regarding genetics 
 (1) None 
 (2) General Biology course 
 (3) Specific course on Genetics 





















Knowledge regarding genomics and precision medicine: 
 
Rate your knowledge on a scale of 1 to 5 on the following subjects  
(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above average 
understanding; 5=expert understanding),  
 
please rate your knowledge of the following: 
 
Pharmacogenomics   
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Genetics of complex disease None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Carrier Status Testing  None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Basic genetic principles  None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Precision medicine None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
The risks of pharmacogenomic 
testing 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
The benefits of pharmacogenomic 
testing 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Gene-environment interactions None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
How to interpret 
pharmacogenomic test results 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
How pharmacogenomic test results 
are used in clinical practice 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
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How pharmacogenomic test results 
are used in clinical practice 
None Minimal Moderate Above 
Average 
Expert 





























Subtle differences in a person’s genome can have a major impact (eg. explain >30% of the 








The product labeling (package insert) for warfarin includes specific recommendations for dosing 




































Attitudes/Perceptions Regarding the Use of Genomics and Precision Medicine in Primary 
Care: 
Do you feel you would benefit from additional education/training in genomic medicine?  
 Yes (0) 
 No (1) 
 
Please indicate your preferred mode of learning about genomic medicine:  
 (0) Professional meetings 
 (2) Laboratory representative 
 (3) Peer-reviewed publications/journals 
 (4) Online CME learning 
 (5) In-person CME learning (e.g., grand rounds or other in-house seminars) 
 (6) Just-in-time (point-of-care, reminder notice through electronic medical record) 
 (7) Other (please specify) ____________________ 
 
 
Do you plan on personally undergoing genetic testing as part of this course?  
 Yes (0) 
 No (1) 
  
 Would you have made the same decision if you had been told the result would be entered into  
your medical record? 
 Yes (0) 
 No (1) 
Would you have made the same decision if this course also offered genetic testing to determine  
your predisposition to a variety of common diseases (e.g. diabetes, cardiovascular disease)? 
 Yes (0) 
















In general, how useful do you feel the following testing will be to you in the clinical setting? 
 









 1  2  3  4  
 









 1  2  3  4  
 









 1  2  3  4  
 











 1  2  3  4  
 
 
Most primary care physicians have enough knowledge to help individuals interpret the results of 
the following types of tests: 
(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above 
average understanding; 5=expert understanding)  
 
Pharmacogenomic Testing None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Prenatal Carrier Testing None Minimal Moderate Above 
Average 
Expert 




Cancer Genetic Carrier Testing None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Direct To Consumer Testing 
 
None Minimal Moderate Above 
Average 
Expert 






Most primary care physicians have enough knowledge to ensure patients understand the 
risks and benefits surrounding the following types of tests: 
(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above 
average understanding; 5=expert understanding)  
 
Pharmacogenomic Testing None Minimal Moderate Above 
Average 
Expert 




Prenatal Carrier Testing None Minimal Moderate Above 
Average 
Expert 




Cancer Genetic Carrier Testing None Minimal Moderate Above 
Average 
Expert 




Direct To Consumer Testing 
 
None Minimal Moderate Above 
Average 
Expert 





All primary care providers 
should be required to have 





Disagree Neutral Agree Strongly 
Agree 




Part of a primary care 
physician’s role should 






Disagree Neutral Agree Strongly 
Agree 




In the future, 
pharmacogenomic testing will 
routinely be used to optimize 




Disagree Neutral Agree Strongly 
Agree 





How likely is it that knowing 
genetic information about 
yourself would lead to 













PGT companies provide an 
accurate analysis and 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
  
Most people can accurately 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 






Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable 
explaining the process of 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable 
discussing pharmacogenomic 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
 
If you were to undergo PGT, would you share your results with your personal physician? 
 Yes (0) 
 No (1) 
 
If you were to undergo PGT, would you ask a health care provider for help in interpreting the 
results? 
 Yes (0) 
 No (1) 
 
Would you at this time recommend PGT for a patient? 
 Yes (0) 
 No (1) 
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Prior to this course were you previously aware of direct-to-consumer genetics testing (e.g 
23andMe, etc.)?  
 Yes (0) 
 No (1) 
 
Have you personally ever had genetic testing performed?  
 Yes (0) 
 No (1) 
 
Has anyone close to you had genetic testing performed (e.g., parent, child, sibling, friend)?  
 Yes (0) 
 No (1) 
 
In your practice, have you had a patient bring genetic test results to you?    
 Yes (0) 
 No (1) 
 
In past year, how often have you ordered or used the following genetic testing services to 
manage your patients? 
 
a. Pharmacogenomics? 
 (0)  Never or not familiar with the testing 
 (1) Rarely (<5 per year) 
 (2) Occasionally (6-10 per year) 
 (3) Frequently (11+ per year) 
 
b. Diagnostic genetic testing (e.g. Huntington’s Chorea)? 
 (0)  Never or not familiar with the testing 
 (1) Rarely (<5 per year) 
 (2) Occasionally (6-10 per year) 
 (3) Frequently (11+ per year) 
 
c. Carrier Testing (e.g. CF, Tay-Sachs) 
 (0)  Never or not familiar with the testing 
 (1) Rarely (<5 per year) 
 (2) Occasionally (6-10 per year) 






d. Cancer Risk Testing (e.g. BRCA, Lynch) 
 (0)  Never or not familiar with the testing 
 (1) Rarely (<5 per year) 
 (2) Occasionally (6-10 per year) 
 (3) Frequently (11+ per year) 
 
In the past year, which testing technologies have you ordered or used to manage your patients 
(check all that apply)?  
 (0) Not applicable (have not used) 
 (1) Karyotyping 
 (2) Single gene tests 
 (3) Multiple gene panels 
 (4) Microarray-based testing 
 (5) Targeted sequencing 
 (6) Whole genome or exome sequencing 
















Appendix B.2.2 Post-Course Survey 
Knowledge of Genetics and Pharmacogenomics: 
 
Rate your knowledge on a scale of 1 to 5 on the following subjects  
(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above average 
understanding; 5=expert understanding) 
 
please rate your knowledge of the following: 
Pharmacogenomics   None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Genetics of complex disease None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Carrier Status Testing  None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Basic genetic principles  None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Precision medicine None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
The risks of pharmacogenomic 
testing 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
The benefits of pharmacogenomic 
testing 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Gene-environment interactions None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
How to interpret 
pharmacogenomic test results 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
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How pharmacogenomic test results 
are used in clinical practice 
None Minimal Moderate Above 
Average 
Expert 





Humans are over 99% identical at the DNA level. 
 True (0) 
 False (1) 
 
Most cells in the body contain 47 chromosomes. 
 True (0) 
 False (1) 
 
Some genetic conditions, such as sickle cell anemia, are caused by a mutation in a single gene. 
 True (0) 
 False (1) 
 
A person’s genotype is not expected to change over a person’s lifetime. 
 True (0) 
 False (1) 
 
Most common diseases, such as diabetes and heart disease, are caused by a change in a single 
gene. 
 True (0) 
 False (1) 
 
Prevalence of many Mendelian diseases differs by ethnic groups. 
 True (0) 
 False (1) 
 
Subtle differences in a person’s genome can have a major impact (eg. explain >30% of the 
overall variability) on a drug’s pharmacokinetics and/or pharmacodynamics. 
 True (0) 
 False (1) 
 
Drugs have pharmacogenomic information in their FDA approved labeling. 
 True (0) 
 False (1) 
 
The product labeling (package insert) for warfarin includes specific recommendations for dosing 
in patients that have specific genetic variants. 
 True (0) 




Pharmacogenomic testing is currently available for most medications. 
 True (0) 
 False (1) 
 
Personal genomic testing is available to consumers and can be done without a prescription. 
 True (0) 




Attitudes/Perceptions Regarding the Use of Pharmacogenomics and Precision Medicine in 
Primary Care: 
Do you feel you would benefit from additional education/training in genomic medicine?  
 Yes (0) 
 No (1) 
 
Please indicate your preferred mode of learning about genomic medicine:  
 (0) Professional meetings 
 (2) Laboratory representative 
 (3) Peer-reviewed publications/journals 
 (4) Online CME learning 
 (5) In-person CME learning (e.g., grand rounds or other in-house seminars) 
 (6) Just-in-time (point-of-care, reminder notice through electronic medical record) 
 (7) Other (please specify) ____________________ 
 
Did you personally undergoing genetic testing as part of this course?  
 Yes (0) 
 No (1) 
  
 Would you have made the same decision if you had been told the result would be entered into  
your medical record? 
 Yes (0) 
 No (1) 
Would you have made the same decision if this course also offered genetic testing to determine  
your predisposition to a variety of common diseases (e.g. diabetes, cardiovascular disease)? 
 Yes (0) 















In general, how useful do you feel the following testing will be to you in the clinical setting? 
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 1  2  3  4  
 









 1  2  3  4  
 









 1  2  3  4  
 











 1  2  3  4  
 
 
Most primary care physicians have enough knowledge to help individuals interpret the 
results of the following types of tests: 
(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above 
average understanding; 5=expert understanding)  
 
Pharmacogenomic Testing None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Prenatal Carrier Testing None Minimal Moderate Above 
Average 
Expert 




Cancer Genetic Carrier Testing None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Direct To Consumer Testing 
 
None Minimal Moderate Above 
Average 
Expert 





Most primary care physicians have enough knowledge to ensure patients understand the 
risks and benefits surrounding the following types of tests: 
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(1=no knowledge; 2=minimal understanding; 3=moderate understanding; 4=above 
average understanding; 5=expert understanding)  
 
Pharmacogenomic Testing None Minimal Moderate Above 
Average 
Expert 




Prenatal Carrier Testing None Minimal Moderate Above 
Average 
Expert 




Cancer Genetic Carrier Testing None Minimal Moderate Above 
Average 
Expert 




Direct To Consumer Testing 
 
None Minimal Moderate Above 
Average 
Expert 






All primary care providers 
should be required to have 





Disagree Neutral Agree Strongly 
Agree 




Part of a primary care 
physician’s role should 






Disagree Neutral Agree Strongly 
Agree 




In the future, 
pharmacogenomic testing will 
routinely be used to optimize 




Disagree Neutral Agree Strongly 
Agree 




How likely is it that knowing 








yourself would lead to 
changes in your own 
behavior? 
 




PGT companies provide an 
accurate analysis and 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
  
Most people can accurately 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 






Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable 
explaining the process of 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable 
discussing pharmacogenomic 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable 







Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
 
If you were to undergo PGT, would you share your results with your personal physician? 
 Yes (0) 
 No (1) 
 
If you were to undergo PGT, would you ask a health care provider for help in interpreting the 
results? 
 Yes (0) 
 No (1) 
 
Would you at this time recommend PGT for a patient? 
 Yes (0) 
 No (1) 
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Prior to this course were you previously aware of direct-to-consumer genetics testing (e.g 
23andMe, etc.)?  
 Yes (0) 
 No (1) 
 
Have you personally ever had genetic testing performed?  
 Yes (0) 
 No (1) 
 
Has anyone close to you had genetic testing performed (e.g., parent, child, sibling, friend)?  
 Yes (0) 
 No (1) 
 
In your practice, have you had a patient bring genetic test results to you?    
 Yes (0) 
 No (1) 
 
In past year, how often have you ordered or used the following genetic testing services to 
manage your patients? 
 
a. Pharmacogenomics? 
 (0)  Never or not familiar with the testing 
 (1) Rarely (<5 per year) 
 (2) Occasionally (6-10 per year) 
 (3) Frequently (11+ per year) 
 
b. Diagnostic genetic testing (e.g. Huntington’s Chorea)? 
 (0)  Never or not familiar with the testing 
 (1) Rarely (<5 per year) 
 (2) Occasionally (6-10 per year) 
 (3) Frequently (11+ per year) 
 
c. Carrier Testing (e.g. CF, Tay-Sachs) 
 (0)  Never or not familiar with the testing 
 (1) Rarely (<5 per year) 
 (2) Occasionally (6-10 per year) 





d. Cancer Risk Testing (e.g. BRCA, Lynch) 
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 (0)  Never or not familiar with the testing 
 (1) Rarely (<5 per year) 
 (2) Occasionally (6-10 per year) 
 (3) Frequently (11+ per year) 
 
In the past year, which testing technologies have you ordered or used to manage your patients 
(check all that apply)?  
 (0) Not applicable (have not used) 
 (1) Karyotyping 
 (2) Single gene tests 
 (3) Multiple gene panels 
 (4) Microarray-based testing 
 (5) Targeted sequencing 
 (6) Whole genome or exome sequencing 




What elements of the course will you expect to be most difficult to master in your routine 
practice?  
What suggestions do you have for overcoming these difficulties?  
Do you have any other comments, questions, or feedback? 
 
The following have been valuable to you in your learning experience:  
 




   Strongly 
Agree 
 1  2  3  4  5 
 
2. The live course Strongly 
Disagree 
   Strongly 
Agree 
 1  2  3  4  5 
 





   Strongly 
Agree 
 1  2  3  4  5 
 




   Strongly 
Agree 
 1  2  3  4  5 
 
5. Clear learning objectives Strongly 
Disagree 
   Strongly 
Agree 
 1  2  3  4  5 
 
6. Detailed course outline Strongly 
Disagree 
   Strongly 
Agree 
 1  2  3  4  5 
 




   Strongly 
Agree 





Appendix C MWGS Surveys 
Appendix C.1 Clinician Survey Questions 
Demographics: 
 
What is your current age? 
 18 to 24 years 
 25 to 34 years 
 35 to 44 years 
 45 to 54 years 
 55 to 64 years 
 Age 65 or older 
 
Please select the gender you identify with: 
 (0) Male 
 (1) Female 
 (2) Gender Variant/Non-conforming 
 (3) Prefer Not to Answer 
 
What is your ethnicity? (select all that apply) 
 (0) Black or African American 
 (1) White 
 (2) Hispanic or Latino 
 (3) Native American or American Indian 
 (4) Asian/Pacific Islander 
 (5) Middle Eastern/North African 
 
What best describes your current position (select one only): 
 (1) M.D./D.O. 
 (2) NP/PA 
 (3) PharmD/RPh 
 (4) RN/MA 
 (5) Staff 
 (6) Insurance Affiliate 














Please select what best describes your previous education regarding genetics: 
 (1) None 
 (2) Biology course 
 (3) Specific course on genetics 
 (4) Specific course/training in pharmacogenomics 
 
Please indicate your preferred mode of learning about medical genetics:  
 (0) Professional meetings 
 (1) Laboratory representative 
 (2) Peer-reviewed publications/journals 
 (3) Online CME learning 
 (4) In-person CME learning (e.g., grand rounds or other in-house seminars) 
 (5) Just-in-time (point-of-care, reminder notice through electronic medical record) 
 (6) Other (please specify) ____________________ 
 
Do you plan on personally undergoing genetic testing as part of this course?  
 (0) Yes 
 (1) No  
 
a. Would you have made the same decision if this course also offered genetic testing to 
determine your predisposition to a variety of common diseases (e.g. diabetes, 
cardiovascular disease)? 
 (0) Yes 
 (1) No 
 
b. Did concerns regarding any of the following affect your decision to undergo testing.  
 (0) Data security/privacy 
 (1) Impact on health insurance eligibility 
 (2) Impact on life insurance eligibility 
 (3) Employment discrimination 





Have you personally ever had genetic testing performed?  
 Yes (0) 
 No (1) 
 
Has anyone close to you had genetic testing performed (e.g., parent, child, sibling, friend)?  
 Yes (0) 
 No (1) 
 
In your practice, have you had a patient bring genetic test results to you?    
 Yes (0) 
 No (1) 
 
If yes, which testing technologies have you had a patient bring into you? (check all 
that apply) 
 (0) Not applicable (have not used) 
 (1) Karyotyping 
 (2) Single gene tests 
 (3) Multiple gene panels 
 (4) Microarray-based testing 
 (5) Targeted sequencing 
 (6) Whole genome or exome sequencing 
 (7) Direct to Consumer testing 
 (8) Not sure of the type  
 
In the past year, which testing technologies have you ordered or used to manage your patients 
(check all that apply)?  
 (0) Not applicable (have not used) 
 (1) Karyotyping 
 (2) Single gene tests 
 (3) Multiple gene panels 
 (4) Microarray-based testing 
 (5) Targeted sequencing 
 (6) Whole genome or exome sequencing 






Knowledge of Genetics and Pharmacogenomics: 
Rate your level of understanding on a scale of 1 to 5 for the following subjects:  
Precision medicine None Minimal Moderate Above 
Average 
Expert 




None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Basic genetic concepts  None Minimal Moderate Above 
Average 
Expert 




None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Applications of whole 
genome sequencing in 
clinical practice   
None Minimal Moderate Above 
Average 
Expert 




None Minimal Moderate Above 
Average 
Expert 




None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Integration of genetic 
testing results into 
patient health record 
None Minimal Moderate Above 
Average 
Expert 
 1  2  3  4  5 
 
Ethical, legal, and 
societal implications 
of genetic testing. 
None Minimal Moderate Above 
Average 
Expert 










Please select the most accurate answer. 
 
Precision medicine takes into account individual variability in the genome to personalize 
medical management. Common clinical applications of precision medicine include all of the 
following EXCEPT:  
 Use of pharmacogenomic (PGx) test results to target medication prescribing. 
 Use of polygenic risk scores (PRS) to assess a patient’s risk for common diseases. 
 Use of panel genetic testing to assess a patient’s risk for common cancers. 
 Use of carrier genetic testing to assess a patient’s risk of being a carrier for a rare disease. 
 Use of expansive genetic sequencing to assess a patient’s risk of having a genetic 
condition. 
 
Whole genome sequencing cannot detect: 
 Single nucleotide variants (SNVs) 
 Large structural variants 
 Changes in methylation 
 Copy number variations 
 Mitochondrial DNA variants 
 
Mutations are changes in an individual’s DNA and results in a different version of the gene. 
Which of the options below is an example of a mutation that, if considered independently, 
would not impact medical management? 
 A patient with one pathogenic mutation in CYP2C19. 
 A patient with Trisomy 21. 
 A patient with one pathogenic mutation in BRCA1. 
 A patient with one pathogenic mutation in CFTR. 
 
Genetic mutations are classified on a scale from benign to uncertain to pathogenic per 
ACMG-AMP guidelines. A patient has genetic results that report a variant of uncertain 
significance. Which of the following is not a possibility that should be discussed with the 
patient?: 
 As the lab gets more data, they reclassify the variant as benign. 
 As the lab gets more data, they reclassify the variant as pathogenic. 
 In hopes of getting more data, the lab offers testing only for family members that 
are similarly affected to help reclassify the variant. 
 In hopes of getting more data, the lab requests more phenotypic data to help reclassify the 
variant. 
 
Whole genome sequencing technology cannot clinically be used at this time to: 
 Diagnose an individual with a predisposition to develop cancer. 
 Diagnose an individual with a predisposition to develop complex disease. 
 Identify an individual as a carrier for a condition. 




When consenting a patient to receive genetic testing, which of the following results should be 
discussed as a potential result of genome sequencing: 
 Pathogenic mutations 
 Uncertain mutations 
 Secondary mutations 
 Benign mutations 
 Mosaic mutations 
 
A pathogenic result found on whole genome sequencing should prompt a provider to do all 
of the following except: 
 Refer the patient to a genetics provider for further follow-up. 
 Identify appropriate resources for the patient. 
 Test family members for the pathogenic finding. 
 Interrogate the result using online resources such as ClinVar and OMIM. 
 
A patient’s whole genome sequencing results: 
 Can be routinely integrated into current common EHR systems. 
 Should not be expressly used in patient medical management. 
 Should not be reanalyzed because they already reflect all pathogenic variants. 
 Should be stored as a diagnostic report and not as raw data in the EHR. 
 
Which statement concerning the ethical, legal, and social implications of whole genome 
sequencing testing true: 
 The Genetic Information Non-Discrimination Act protects patients from being 
discriminated against based on their genetic testing results when purchasing disability 
insurance. 
 All pathogenic findings, including secondary findings should always be reported to 
patients. 
 Genetic testing for adult onset conditions in minors should always be conducted if 
there is a known pathogenic mutation in a family member. 
 Genetic testing results are protected under HIPAA.  
 161 
Attitudes/Perceptions Regarding the Use of Whole Genome Sequencing and Precision 
Medicine: 
In general, how useful do you feel the following WGS testing results will be to you in the 
clinical setting? 
 








 1  2  3  4  5 
 








 1  2  3  4  5 
 
Genetic Factors of Complex 






















 1  2  3  4  5 
 
 
In general, I have enough knowledge to help individuals interpret the results of the following 
types of results: 
 








 1  2  3  4  5 
 








 1  2  3  4  5 
 
Genetic Factors of Complex 































In general, I have enough knowledge to ensure patients understand the risks and benefits 
surrounding the following types of results: 
(1=strongly disagree; 2= disagree; 3=neutral; 4=agree; 5=strongly agree)  
 








 1  2  3  4  5 
 








 1  2  3  4  5 
 
Genetic Factors of Complex 


























All clinicians should be required to 




Disagree Neutral Agree Strongly 
Agree 




Part of a clinician’s role should include 





Disagree Neutral Agree Strongly 
Agree 




In the future, pharmacogenomic testing 
will routinely be used to optimize drug 




Disagree Neutral Agree Strongly 
Agree 









Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable explaining 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
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I would feel comfortable discussing 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable referring a 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
 
Would you at this time recommend genomic testing for a patient? 
 Yes (0) 
 No (1) 
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Course Expectations (Providers/Staff): 
What elements of the course will you expect to be most difficult to master in your routine 
practice?  
What suggestions do you have for overcoming these difficulties?  
Do you have any other comments, questions, or feedback? 
 
The following have been valuable to you in your learning experience:  




   Strongly 
Agree 
 1  2  3  4  5 
 





   Strongly 
Agree 
 1  2  3  4  5 
 
Clear learning objectives Strongly 
Disagree 
   Strongly 
Agree 
 1  2  3  4  5 
 
Detailed course outline Strongly 
Disagree 
   Strongly 
Agree 











Appendix C.2 KOLs Survey Questions 
Demographics: 
What is your current age? 
 18 to 24 years 
 25 to 34 years 
 35 to 44 years 
 45 to 54 years 
 55 to 64 years 
 Age 65 or older 
 
Please select the gender you identify with: 
 (0) Male 
 (1) Female 
 (2) Gender Variant/Non-conforming 
 (3) Prefer Not to Answer 
 
What is your ethnicity? (select all that apply) 
 (0) Black or African American 
 (1) White 
 (2) Hispanic or Latino 
 (3) Native American or American Indian 
 (4) Asian/Pacific Islander 
 (5) Middle Eastern/North African 
 
What best describes your current position (select one only): 
 (1) M.D./D.O. 
 (2) NP/PA 
 (3) PharmD/RPh 
 (4) RN/MA 
 (5) Staff 
 (6) Insurance Affiliate 
 (7) other: ________________ 
 










Please select what best describes your previous education regarding genetics: 
 (1) None 
 (2) Biology course 
 (3) Specific course on genetics 
 (4) Specific course/training in pharmacogenomics 
 
Please indicate your preferred mode of learning about medical genetics:  
 (0) Professional meetings 
 (1) Laboratory representative 
 (2) Peer-reviewed publications/journals 
 (3) Online CME learning 
 (4) In-person CME learning (e.g., grand rounds or other in-house seminars) 
 (5) Just-in-time (point-of-care, reminder notice through electronic medical record) 
 (6) Other (please specify) ____________________ 
 
Do you plan on personally undergoing genetic testing as part of this course?  
 (0) Yes 
 (1) No  
 
a. Would you have made the same decision if this course also offered genetic testing to 
determine your predisposition to a variety of common diseases (e.g. diabetes, 
cardiovascular disease)? 
 (0) Yes 
 (1) No 
 
b. Did concerns regarding any of the following affect your decision to undergo testing.  
 (0) Data security/privacy 
 (1) Impact on health insurance eligibility 
 (2) Impact on life insurance eligibility 
 (3) Employment discrimination 
 (4) Fear of learning results (ie., cancer risk, Alzheimer’s risk) 
 
Have you personally ever had genetic testing performed?  
 Yes (0) 
 No (1) 
 
Has anyone close to you had genetic testing performed (e.g., parent, child, sibling, friend)?  
 Yes (0) 
 No (1) 
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In your experience, have you ever brought genetic test results to a clinician for use in your 
medical management?    
 Yes (0) 
 No (1) 
 
If yes, which testing technologies have you brought into your clinician’s office? (check 
all that apply) 
 (0) Not applicable (have not used) 
 (1) Karyotyping 
 (2) Single gene tests 
 (3) Multiple gene panels 
 (4) Microarray-based testing 
 (5) Targeted sequencing 
 (6) Whole genome or exome sequencing 
 (7) Direct to Consumer testing 
 (8) Not sure of the type  
   
In the past year, which testing technologies have you had a clinician order or used to manage 
your medical care (check all that apply)?  
 (0) Not applicable (have not used) 
 (1) Karyotyping 
 (2) Single gene tests 
 (3) Multiple gene panels 
 (4) Microarray-based testing 
 (5) Targeted sequencing 
 (6) Whole genome or exome sequencing 











Knowledge of Genetics and Precision Medicine: 
 
Rate your level of understanding on a scale of 1 to 5 for the following subjects:  
Precision 
medicine 
None Minimal Moderate Above 
Average 
Expert 




None Minimal Moderate Above 
Average 
Expert 




None Minimal Moderate Above 
Average 
Expert 





clinical practice   
None Minimal Moderate Above 
Average 
Expert 





None Minimal Moderate Above 
Average 
Expert 







None Minimal Moderate Above 
Average 
Expert 






None Minimal Moderate Above 
Average 
Expert 


















Please select the most accurate answer. 
 
Precision medicine takes into account individual variability in the genome to personalize 
medical management. Common clinical applications of precision medicine include all of the 
following EXCEPT:  
 Use of pharmacogenomic (PGx) test results to target medication prescribing. 
 Use of polygenic risk scores (PRS) to assess a patient’s risk for common diseases. 
 Use of panel genetic testing to assess a patient’s risk for common cancers. 
 Use of carrier genetic testing to assess a patient’s risk of being a carrier for a rare disease. 
 Use of expansive genetic sequencing to assess a patient’s risk of having a genetic 
condition. 
 
Mutations are changes in an individual’s DNA and results in a different version of the gene. 
Which of the options below is an example of a mutation that, if considered independently, 
would not impact medical management? 
 A patient with one harmful mutation associated with a dominant change in medicine 
metabolism, such as Clopidogrel. 
 A patient with a different number of chromosomes than expected, like Down Syndrome. 
 A patient with one harmful mutation for in a common cancer risk gene, like BRCA1. 
 A patient with one harmful mutation associated with a recessive condition, like 
Cystic Fibrosis. 
 
Whole genome sequencing cannot detect: 
 Single nucleotide variants (SNVs) 
 Large structural variants 
 Changes in methylation 
 Copy number variations 
 Mitochondrial DNA variants  
 
Whole genome sequencing technology cannot clinically be used at this time to: 
 Diagnose an individual with a predisposition to develop cancer. 
 Diagnose an individual with a predisposition to develop complex disease. 
 Diagnose an individual as a carrier for a condition. 
 Diagnose an individual with a genetic syndrome. 
 
Studies have shown that the use of whole genome sequencing: 
 Increases overall cost of healthcare. 
 Decreases testing turnaround time. 
 Has a diagnostic yield higher than other first line genetic testing options, such as 
SNP microarray. 







A patient’s whole genome sequencing results: 
 Can be routinely integrated into current common EHR systems. 
 Should not be expressly used in patient medical management. 
 Should not be reanalyzed because they already reflect all pathogenic variants. 
 Should be stored as a diagnostic report and not as raw data. 
 
Which statement concerning the ethical, legal, and social implications of whole genome 
sequencing testing true: 
 The Genetic Information Non-Discrimination Act protects patients from being 
discriminated against based on their genetic testing results when purchasing disability 
insurance. 
 All pathogenic findings, including secondary findings, should always be reported to 
patients. 
 Genetic testing for adult onset conditions in minors should always be conducted if there 
is a known pathogenic mutation in a family member. 
Genetic testing results are protected under HIPAA. 
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Attitudes/Perceptions Regarding the Use of Whole Genome Sequencing and Precision 
Medicine: 
In general, how useful do you feel the following WGS testing results will be to your medical 
management? 
 








 1  2  3  4  5 
 








 1  2  3  4  5 
 
Genetic Factors of Complex 






















 1  2  3  4  5 
 
 
In general, clinicians have enough knowledge to help individuals interpret the results of the 
following types of results: 
 








 1  2  3  4  5 
 








 1  2  3  4  5 
 
Genetic Factors of Complex 































In general, clinicians have enough knowledge to ensure patients understand the risks and benefits 
surrounding the following types of results: 
(1=strongly disagree; 2= disagree; 3=neutral; 4=agree; 5=strongly agree)  
 








 1  2  3  4  5 
 








 1  2  3  4  5 
 
Genetic Factors of Complex 


























All clinicians should be required to 




Disagree Neutral Agree Strongly 
Agree 




Part of a clinician’s role should include 





Disagree Neutral Agree Strongly 
Agree 




In the future, pharmacogenomic testing 
will routinely be used to optimize drug 




Disagree Neutral Agree Strongly 
Agree 




I would feel comfortable having 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
I would feel comfortable discussing 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
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I would feel comfortable discussing 




Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 





Disagree Neutral Agree Strongly 
Agree 
 1  2  3  4  5 
 
 
Would you at this time recommend genomic testing insurance coverage? 
 Yes (0) 




The following have been valuable to you in your learning experience:  




   Strongly 
Agree 
 1  2  3  4  5 
 





   Strongly 
Agree 
 1  2  3  4  5 
 
Clear learning objectives Strongly 
Disagree 
   Strongly 
Agree 
 1  2  3  4  5 
 
Detailed course outline Strongly 
Disagree 
   Strongly 
Agree 
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